US20060275327A1 - In vivo modulation of neuronal transport - Google Patents
In vivo modulation of neuronal transport Download PDFInfo
- Publication number
- US20060275327A1 US20060275327A1 US11/375,093 US37509306A US2006275327A1 US 20060275327 A1 US20060275327 A1 US 20060275327A1 US 37509306 A US37509306 A US 37509306A US 2006275327 A1 US2006275327 A1 US 2006275327A1
- Authority
- US
- United States
- Prior art keywords
- fragment
- protein
- tetanus toxin
- ttc
- neurotrophic factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001727 in vivo Methods 0.000 title claims abstract description 30
- 230000001537 neural effect Effects 0.000 title claims description 51
- 239000012634 fragment Substances 0.000 claims abstract description 133
- 230000032258 transport Effects 0.000 claims abstract description 62
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 47
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 241001465754 Metazoa Species 0.000 claims abstract description 33
- 210000000278 spinal cord Anatomy 0.000 claims abstract description 28
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 11
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 8
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 8
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 8
- 230000008827 biological function Effects 0.000 claims abstract description 7
- 230000009844 retrograde axon cargo transport Effects 0.000 claims abstract description 6
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 109
- 229940118376 tetanus toxin Drugs 0.000 claims description 109
- 108090000623 proteins and genes Proteins 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 91
- 210000002569 neuron Anatomy 0.000 claims description 88
- 102000004169 proteins and genes Human genes 0.000 claims description 85
- 210000000715 neuromuscular junction Anatomy 0.000 claims description 81
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 70
- 210000004027 cell Anatomy 0.000 claims description 69
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 60
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 57
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 57
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 57
- 108020001507 fusion proteins Proteins 0.000 claims description 54
- 102000037865 fusion proteins Human genes 0.000 claims description 52
- 210000003205 muscle Anatomy 0.000 claims description 48
- 239000003900 neurotrophic factor Substances 0.000 claims description 48
- 102000015534 trkB Receptor Human genes 0.000 claims description 37
- 108010064880 trkB Receptor Proteins 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 32
- 239000000018 receptor agonist Substances 0.000 claims description 29
- 229940044601 receptor agonist Drugs 0.000 claims description 29
- 102000005962 receptors Human genes 0.000 claims description 26
- 108020003175 receptors Proteins 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 239000005090 green fluorescent protein Substances 0.000 claims description 25
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 24
- 102100033857 Neurotrophin-4 Human genes 0.000 claims description 24
- 108090000099 Neurotrophin-4 Proteins 0.000 claims description 24
- 229940097998 neurotrophin 4 Drugs 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 24
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 23
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 23
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 23
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 20
- 210000004556 brain Anatomy 0.000 claims description 20
- 102000004230 Neurotrophin 3 Human genes 0.000 claims description 19
- 210000000225 synapse Anatomy 0.000 claims description 19
- 229940032018 neurotrophin 3 Drugs 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 230000004913 activation Effects 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 239000002464 receptor antagonist Substances 0.000 claims description 14
- 229940044551 receptor antagonist Drugs 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 11
- 239000003623 enhancer Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 102100033299 Glia-derived nexin Human genes 0.000 claims description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 6
- 108700008625 Reporter Genes Proteins 0.000 claims description 6
- 238000001415 gene therapy Methods 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 108090000426 Caspase-1 Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 5
- 230000002588 toxic effect Effects 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 230000004572 zinc-binding Effects 0.000 claims description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 3
- 102100035904 Caspase-1 Human genes 0.000 claims description 3
- 102000004533 Endonucleases Human genes 0.000 claims description 3
- 108010042407 Endonucleases Proteins 0.000 claims description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 3
- 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 claims description 3
- 101710102218 Serine protease inhibitor Proteins 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 210000000663 muscle cell Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 108010005113 Serpin E2 Proteins 0.000 claims 4
- 102000013275 Somatomedins Human genes 0.000 claims 4
- 208000029033 Spinal Cord disease Diseases 0.000 claims 4
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 1
- 101710155777 mRNA export factor ICP27 homolog Proteins 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 abstract 3
- 238000002347 injection Methods 0.000 description 48
- 239000007924 injection Substances 0.000 description 48
- 229940090044 injection Drugs 0.000 description 47
- 238000002372 labelling Methods 0.000 description 43
- 210000002161 motor neuron Anatomy 0.000 description 30
- 210000004940 nucleus Anatomy 0.000 description 27
- 150000002632 lipids Chemical class 0.000 description 26
- 230000004807 localization Effects 0.000 description 25
- 238000010186 staining Methods 0.000 description 25
- 210000005036 nerve Anatomy 0.000 description 24
- 101150056950 Ntrk2 gene Proteins 0.000 description 23
- 230000002990 hypoglossal effect Effects 0.000 description 23
- 230000037361 pathway Effects 0.000 description 20
- 239000012528 membrane Substances 0.000 description 19
- 230000001419 dependent effect Effects 0.000 description 18
- 231100000765 toxin Toxicity 0.000 description 18
- 239000003053 toxin Substances 0.000 description 18
- 108700012359 toxins Proteins 0.000 description 18
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 210000002504 synaptic vesicle Anatomy 0.000 description 15
- 230000001927 transneuronal effect Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 108010005774 beta-Galactosidase Proteins 0.000 description 13
- 101150066555 lacZ gene Proteins 0.000 description 13
- 210000003050 axon Anatomy 0.000 description 12
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 102000015336 Nerve Growth Factor Human genes 0.000 description 10
- 238000009739 binding Methods 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 230000012202 endocytosis Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 229940053128 nerve growth factor Drugs 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 238000010255 intramuscular injection Methods 0.000 description 8
- 239000007927 intramuscular injection Substances 0.000 description 8
- 230000007441 retrograde transport Effects 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000000946 synaptic effect Effects 0.000 description 8
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 7
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 7
- 102000005853 Clathrin Human genes 0.000 description 7
- 108010019874 Clathrin Proteins 0.000 description 7
- 210000004323 caveolae Anatomy 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 229930193282 clathrin Natural products 0.000 description 7
- 230000002121 endocytic effect Effects 0.000 description 7
- 230000003518 presynaptic effect Effects 0.000 description 7
- 210000002027 skeletal muscle Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000003904 Caveolin 3 Human genes 0.000 description 6
- 108090000268 Caveolin 3 Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 238000013528 artificial neural network Methods 0.000 description 6
- 210000005056 cell body Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 150000002270 gangliosides Chemical class 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000003957 neurotransmitter release Effects 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 102000009016 Cholera Toxin Human genes 0.000 description 5
- 108010049048 Cholera Toxin Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101000584505 Homo sapiens Synaptic vesicle glycoprotein 2A Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101710138657 Neurotoxin Proteins 0.000 description 5
- 102100030701 Synaptic vesicle glycoprotein 2A Human genes 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000003376 axonal effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000008045 co-localization Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000001640 nerve ending Anatomy 0.000 description 5
- 239000002581 neurotoxin Substances 0.000 description 5
- 231100000618 neurotoxin Toxicity 0.000 description 5
- 230000002276 neurotropic effect Effects 0.000 description 5
- 230000007115 recruitment Effects 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 230000005062 synaptic transmission Effects 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000012800 visualization Methods 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 206010043376 Tetanus Diseases 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000004295 hippocampal neuron Anatomy 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 210000000627 locus coeruleus Anatomy 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000003061 neural cell Anatomy 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000003956 synaptic plasticity Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101000783401 Bungarus multicinctus Alpha-bungarotoxin Proteins 0.000 description 3
- 241000193449 Clostridium tetani Species 0.000 description 3
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 3
- 101150111783 NTRK1 gene Proteins 0.000 description 3
- 101150117329 NTRK3 gene Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 3
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004900 c-terminal fragment Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 210000001787 dendrite Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000001153 interneuron Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 230000006576 neuronal survival Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 210000003925 spinal cord interneuron Anatomy 0.000 description 3
- 230000022054 synaptic vesicle endocytosis Effects 0.000 description 3
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 230000028973 vesicle-mediated transport Effects 0.000 description 3
- 230000001720 vestibular Effects 0.000 description 3
- 210000004440 vestibular nuclei Anatomy 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 239000012110 Alexa Fluor 594 Substances 0.000 description 2
- 239000012114 Alexa Fluor 647 Substances 0.000 description 2
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108050000084 Caveolin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 2
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 2
- 101710183811 Glia-derived nexin Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 102000004874 Synaptophysin Human genes 0.000 description 2
- 108090001076 Synaptophysin Proteins 0.000 description 2
- 108030001722 Tentoxilysin Proteins 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000003618 cortical neuron Anatomy 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002339 glycosphingolipids Chemical class 0.000 description 2
- 210000001169 hypoglossal nerve Anatomy 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006662 intracellular pathway Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 210000002284 membrane microdomain Anatomy 0.000 description 2
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- -1 potassium ferricyanide Chemical compound 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004189 reticular formation Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000001679 solitary nucleus Anatomy 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002182 synaptic membrane Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 210000000836 trigeminal nuclei Anatomy 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 2
- NVNPEYQWKCQBBU-ADMXJUBYSA-N (2r,4s,5r,6r)-2-[(2s,3s,4r,5r,6s)-2-[(2r,3s,4s,5s,6s)-3-acetamido-2-[(2s,3r,4s,5s,6r)-4-[(2r,4s,5r,6r)-5-amino-2-carboxy-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxan-2-yl]oxy-6-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-1-(octadecanoyl Chemical compound O[C@@H]1[C@@H](O)[C@H](OC(CNC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@]2(O[C@H]([C@H](N)[C@@H](O)C2)C(O)C(O)CO)C(O)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@]4(O[C@H]([C@H](N)[C@@H](O)C4)C(O)C(O)O[C@@]4(O[C@H]([C@H](N)[C@@H](O)C4)C(O)C(O)CO)C(O)=O)C(O)=O)[C@H](O)[C@H](CO)O3)O)[C@H](O)[C@H](CO)O2)NC(C)=O)[C@H](CO)O1 NVNPEYQWKCQBBU-ADMXJUBYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 101100519159 Arabidopsis thaliana PCR3 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 102000009193 Caveolin Human genes 0.000 description 1
- 102000003727 Caveolin 1 Human genes 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 102000015771 Ciliary Neurotrophic Factor Receptor alpha Subunit Human genes 0.000 description 1
- 108010010079 Ciliary Neurotrophic Factor Receptor alpha Subunit Proteins 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 229910002535 CuZn Inorganic materials 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000823108 Equus caballus Alpha-1-antiproteinase 3 Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 229930183931 Filipin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 101000739876 Homo sapiens Brain-derived neurotrophic factor Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101000773038 Human herpesvirus 7 (strain RK) U21 glycoprotein Proteins 0.000 description 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 101100404651 Mus musculus Ngf gene Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 1
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101150102573 PCR1 gene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000000813 Proto-Oncogene Proteins c-ret Human genes 0.000 description 1
- 108010001648 Proto-Oncogene Proteins c-ret Proteins 0.000 description 1
- 102000015799 Qa-SNARE Proteins Human genes 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 101000993333 Rattus norvegicus Ciliary neurotrophic factor Proteins 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000014388 Synaptic vesicle protein SV2 Human genes 0.000 description 1
- 108050003437 Synaptic vesicle protein SV2 Proteins 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 101800003755 Tetanus toxin heavy chain Proteins 0.000 description 1
- 108010076830 Thionins Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004960 anterior grey column Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229940013767 bupivacaine injection Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000013003 endocytic recycling Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- IMQSIXYSKPIGPD-NKYUYKLDSA-N filipin Chemical compound CCCCC[C@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O IMQSIXYSKPIGPD-NKYUYKLDSA-N 0.000 description 1
- 229950000152 filipin Drugs 0.000 description 1
- IMQSIXYSKPIGPD-UHFFFAOYSA-N filipin III Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O IMQSIXYSKPIGPD-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 108010055409 ganglioside receptor Proteins 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 229930186900 holotoxin Natural products 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000051542 human BDNF Human genes 0.000 description 1
- 102000052654 human GDNF Human genes 0.000 description 1
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003585 interneuronal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000013554 lipid monolayer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000001611 motor endplate Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 108010008500 mouse lysosomal acid lipase Proteins 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000034420 neuronal signal transduction Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000002509 periaqueductal gray Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000016833 positive regulation of signal transduction Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002538 spinal trigeminal nucleus Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000005657 synaptic vesicle exocytosis Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 230000003363 transsynaptic effect Effects 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- This invention relates to the use of part of tetanus toxin for delivering a composition to the central nervous system of a human or animal.
- This invention also relates to a hybrid fragment of tetanus toxin, a polynucleotide that hybridizes with natural tetanus toxin, and a composition containing the tetanus toxin fragment as an active molecule.
- this invention relates to a vector comprising a promoter and a nucleic acid sequence encoding the tetanus toxin fragment.
- Tetanus toxin is produced by Clostridium tetani as an inactive, single, polypeptide chain of 150 kD composed of three 50 kD domains connected by protease-sensitive loops.
- the toxin is activated upon selective proteolytic cleavage, which generates two disulfide-linked chains: L (light, 50 kD) and H (heavy, 100 kD) [Montecucco C. and Schiavo G. Q. Rev. Biophys., (1995), 28:423-472].
- fragment C 451 amino acids, also called fragment C.
- fragment B linked to the light chain (fragment A) via a disulfide bond.
- European Patent No. EP 0 030 496B1 showed the retrograde transport of a fragment B-II b to the CNS and was detected after injection in the median muscle of the eye in primary and second order neurons.
- This fragment may consist of “isofragments” obtained by clostridial proteolysis. Later, this fragment B-II b was demonstrated to be identical to fragment C obtained by papain digestion by Eisel et al. [EMBO J., 1986, 5:2495-2502].
- This EP patent also demonstrated the retrograde transport of a conjugate consisting of a I bc tetanus toxin fragment coupled by a disulfide bond to B-II b from axonal endings within the muscle to the motoneuronal perikarya and pericellular spaces.
- the I bc fragment corresponds to the other part obtained by papain digestion as described above by Helting et al.).
- the authors indicated that a conjugate consisting of the fragment B-II b coupled by a disulfide bond to a therapeutic agent was capable of specific fixation to gangliosides and synaptic membranes. No result showed any retrograde axonal transport or a transynaptic transport for such conjugate.
- Another European Patent, No. EP 0 057 140 B1 showed equally the retrograde transport of a fragment II c to the CNS.
- the authors indicated that a conjugate consisting of the fragment II c and a therapeutic agent was capable of specific fixation, but no result illustrated such allegation.
- This fragment II c corresponds to the now called fragment C obtained by papain digestion.
- NMJ neuromuscular junction
- neurotrophins a family of structurally and functionally related proteins, including NGF (Nerve Growth Factor); BDNF (Brain Derived Neurotrophic Factor); Neurotrophin 3 (NT-3) and Neurotrophin 4 (NT-4), not only promote neuronal survival and morphological differentiation, but also can acutely modify synaptic transmission and connectivity in central synapses, thus providing a connection between neuronal activity and synaptic plasticity (McAllister et al., 1999; Poo, 2001; Tao and Poo, 2001).
- TrkB and TrkC are activated by BDNF/NT-4 and NT-3, respectively, and are expressed by motor neurons.
- TrkA which is expressed by sensory neurons, is activated by NGF.
- this invention aids in fulfilling these needs in the art. More particularly, this invention provides a method for in vivo delivery of desired composition into the central nervous system (CNS) of the mammal, wherein the composition comprises a non-toxic proteolytic fragment of tetanus toxin (TT) in association with at least a molecule having a biological function.
- the composition is capable of in vivo retrograde transport and transynaptic transport into the CNS and of being delivered to different areas of the CNS.
- This invention also provides a hybrid fragment of tetanus toxin comprising fragment C and fragment B or a fraction thereof of at least 11 amino acid residues or a hybrid fragment of tetanus toxin comprising fragment C and fragment B or a fraction thereof of at least 11 amino acid residues and a fraction of fragment A devoid of its toxic activity corresponding to the proteolytic domain having a Zinc-binding motif located in the central part of the chain between the amino acids 225 and 245, capable of transferring in vivo a protein, a peptide, or a polynucleotide through a neuromuscular junction and at least one synapse.
- this invention provides a composition comprising an active molecule in association with the hybrid fragment of tetanus toxin (TT) or a variant thereof.
- the composition is useful for the treatment of a patient or an animal affected with CNS disease, which comprises delivering a composition of the invention to the patient or animal.
- the composition of this invention may be useful to elicit a immune response in the patient or animal affected with CNS, which comprises delivering a composition of the invention to the patient or animal.
- this invention provides polynucleotide variant fragments capable of hybridizing under stringent conditions with the natural tetanus toxin sequence.
- the stringent conditions are for example as follows: at 42° C. for 4 to 6 hours in the presence of 6 ⁇ SSC buffer, 1 ⁇ Denhardt's Solution, 1% SDS, and 250 ⁇ g/ml of tRNA.
- (1 ⁇ SSC corresponds to 0.15 M NaCl and 0.05 M sodium citrate;
- 1 ⁇ Denhardt's solution corresponds to 0.02% Ficoll, 0.02% polyvinyl pyrrolidone and 0.02% bovine serum albumin).
- the two wash steps are performed at room temperature in the presence of 0.1 ⁇ SCC and 0.1% SDS.
- a polynucleotide variant fragment means a polynucleotide encoding for a tetanus toxin sequence derived from the native tetanus toxin sequence and having the same properties of transport.
- the invention provides a vector comprising a promoter capable of expression in muscle cells and optionally an enhancer, a nucleic acid sequence coding for the fragment of tetanus toxin of the invention or an amino acid variant fragment of the invention associated with a polynucleotide coding for a protein ⁇ a polypeptide of interest.
- the promoter can be the CMV promoter and preferably the CMV promoter contained in pcDNA 3.1 (In Vitrogen, ref. V790-20), or the promoter ⁇ actin as described in Bronson S. V. et al. (PNAS, 1996, 93:9067-9072).
- the invention provides a vector comprising a promoter capable of expression in neuronal cells or in precursors (such NT2(hNT) precursor cells from Stratagene reference # 204101) and optionally an enhancer, a nucleic acid sequence coding for the fragment of tetanus toxin of the invention or an amino acid variant fragment of the invention associated with a polynucleotide coding for a protein or a polypeptide of interest.
- the promoter can be ⁇ actin (see the above reference).
- One advantage of the present invention comprising the fragment of tetanus toxin (fragment A, B, and C) is to obtain a better transport of the fragment inside the organism compared with fragment C.
- Another advantage of the composition of the invention is to obtain a well defined amino acid sequence and not a multimeric composition. Thus, one can easily manipulate this composition in gene therapy.
- this invention provides a method of modulating the transport in a neuron of a neurotoxin, such as the tetanus toxin, or a fusion protein comprising a fragment C of the tetanus toxin.
- a neurotoxin such as the tetanus toxin
- a fusion protein comprising a fragment C of the tetanus toxin.
- These methods comprise administering neurotrophic factors such as BDNF, NT-4, and GDNF, and agonists and antagonists thereof, to modulate internalization at a neuromuscular junction of a neurotoxin or a fusion protein comprising the TTC fragment according to the invention.
- these methods further comprise administering to the neuron a TrkB receptor agonist or a TrkB receptor antagonist in an amount sufficient to modulate the neuronal transport of the tetanus toxin or the fusion protein.
- modulate and its cognates refer to the capability of a compound acting as either an agonist or an antagonist of a certain reaction or activity.
- modulate therefore, encompasses the terms “increase” and “decrease.”
- the term “decrease” refers to a decrease in the the neuronal transport of a polypeptide in the presence of a modulatory compound, relative to the transport of the polypeptide in the absence of the same compound.
- the neuronal transport of polypeptides can be measured as decribed herein or by techniques generally known in the art.
- the TrkB receptor agonists include neurotrophic factors that activate a TrkB receptor, such as a Brain Derivated Neurotrophic Factor or a Neurotrophin 4.
- the TrkB receptor agonists can also include antibodies that bind to TrkB receptors and activate them. These methods of using TrkB receptor agonists provide useful methods for enhancing the neuronal transport of a tetanus toxin or a tetanus toxin fusion protein.
- the TrkB receptor antagonists include antibodies that bind to a TrkB receptor agonist, such as those described above, and thereby decrease the activation of a TrkB receptor.
- these antibodies can be directed to neurotrophic factors that activate a TrkB receptor, such as a Brain Derivated Neurotrophic Factor or a Neurotrophin 4.
- TrkB receptor antagonists include antibodies that bind to TrkB receptors and inactivate them. These methods of using TrkB receptor agonists provide useful methods for decreasing or preventing the neuronal transport of a tetanus toxin or a tetanus toxin fusion protein.
- these methods further comprise administering to the neuron a GFR ⁇ /cRET receptor agonist or a GFR ⁇ /cRET receptor antagonist in an amount sufficient to modulate the neuronal transport of the tetanus toxin or the fusion protein.
- the GFR ⁇ /cRET receptor agonists include neurotrophic factors that activate a GFR ⁇ /cRET receptor, such as a Glial-Derived Neurotrophic Factor.
- the GFR ⁇ /cRET receptor agonists can also include antibodies that bind to GFR ⁇ /cRET receptors and activate them. These methods of using GFR ⁇ /cRET receptor agonists provide useful methods for enhancing the neuronal transport of a tetanus toxin or a tetanus toxin fusion protein.
- the GFR ⁇ /cRET receptor antagonists include antibodies that bind to a GFR ⁇ /cRET receptor agonist, such as those described above, and thereby decrease the activation of a GFR ⁇ /cRET receptor.
- these antibodies can be directed to neurotrophic factors that activate a GFR ⁇ /cRET receptor, such as a Glial-Derived Neurotrophic Factor.
- GFR ⁇ /cRET receptor antagonists include antibodies that bind to GFR ⁇ /cRET receptors and inactivate them. These methods of using GFR ⁇ /cRET receptor agonists provide useful methods for decreasing or preventing the neuronal transport of a tetanus toxin or a tetanus toxin fusion protein.
- the agonist or antagonist can be administered to neuronal cells that already contain a tetanus toxin or a fusion protein.
- the tetanus toxin or fusion protein can be administered concurrently with or after the administration of the agonist or antagonist.
- the TTC-containing fusion proteins of the present invention comprises a second protein that is encoded by a reporter gene, such as the lac Z gene or the Green Fluorescent Protein gene.
- a reporter gene such as the lac Z gene or the Green Fluorescent Protein gene.
- Such fusion proteins are useful for visualizing modulation of the synaptic plasticity in vivo, including in a human, for example by magnetic resonance imaging.
- the fusion proteins can be used to monitor and detect the effects of a compound, such as a neurotrophic factor, on neuronal transport. In these methods, the compound and the fusion protein are administered to a neuron, and the fusion protein is detected to determine the effect of the compound on the neuronal transport.
- the fusion proteins can be used to detect modifications in trafficking patterns within a restricted neural network, such as those used in known animal models for neurodegenerative diseases.
- the fusion proteins can also be used in screening methods to detect compounds that reduce or prevent neuronal transport of a tetanus toxin. Compounds so identified can be used to prevent or treat tetanus infections.
- the TTC fragment can also be coupled to a neurotrophic factor and administered to a patient to treat CNS pathologies associated with production defects of different factors.
- the TTC fragment could also be used as a vector for modulating interactions with proteins involved in neurodegenerative diseases.
- the present invention also provides compositions comprising a TrkB receptor agonist or a GFR ⁇ /cRET receptor agonist and a fusion protein comprising a fragment C of the tetanus toxin fused to a second protein.
- the TrkB agonist is a neurotrophic factor such as a Brain Derivated Neurotrophic Factor or a Neurotrophin 4.
- the GFR ⁇ /cRET receptor agonist is a neurotrophic factor, such as Glial-Derived Neurotrophic Factor
- FIG. 1 shows the DNA sequence and amino acid sequence of the TTC fragment cloned in pBS:TTC.
- FIG. 2 shows the details of construct pBS:TTC, which is further described in Example 1.
- FIG. 3 depicts pGEX-lacZ-TTC construct.
- FIG. 4 shows construct pGEX:TTC-lacZ.
- FIG. 5 depicts the details of the construct pCMV:lacZ-TTC.
- FIG. 6 shows the confocal immunofluorescence analysis of GFP-TTC membrane traffic at mature mouse LAL NMJs.
- C Two hours after injection as in A, LAL muscle fibers were fixed and labeled for troponin T by indirect immunofluorescence.
- C′ and C′′ Inset is a side view image of a NMJ showing that GFP-TTC staining (green) is located presynaptically.
- D-G LAL was harvested at various times after GFP-TTC injection and NMJ identified in red by labeling with TRITC-a-BTX (D′-G′). D-D′: 5 min; E-E′ 30 min; F-F′: 2 h and G-G′:24 h.
- FIG. 7 shows that BDNF increases GFP-TTC recruitment at the NMJ in a dose-dependent manner.
- FIG. 8 depicts the immunofluorescence visualization of TrkB at the LAL NMJ. Two hours after GFP-TTC injection in LAL, confocal analysis was performed. (A-B) The fusion protein was identified in green directly by GFP fluorescence. (C-D) TrkB, identified (in red) by indirect immunofluorescence (see material and methods), was located at the NMJ. (E-F) However, when the two projections were overlaid, no overlap was found between the TrkB and the GFP-TTC signals.
- FIG. 9 represents the results of experiments elucidating the mechanisms of GFP-TTC recruitment to the NMJ.
- FIG. 10 depicts the localization of GFP-TTC probe in lipid microdomains.
- GFP-TTC was found in detergent resistant membranes (DRMs) (lanes 4-6) isolated from gastroenemius muscle, which also contained the raft marker caveolin-3. A small amount of GFP-TTC was also detected in the soluble fraction (lane 12).
- DRMs detergent resistant membranes
- FIG. 11 shows a comparison of GFP-TTC and CT-b localization in motoneuron cell bodies.
- A ⁇ gal-TTC
- B-E GFP-TTC and CT-b
- intramuscular injection in gastrocnemius muscle mice were perfused intracardially and their spinal cords removed.
- A X-gal reaction on spinal cord transerve sections showed labeling in motoneuron cell bodies but also in neurites (inset).
- B GFP-TTC and CT-b were detected on longitudinal section of spinal cord in a significant number of motoneurons.
- C Probes were detected in vesicles highly concentrated in cell bodies but also in neurites.
- Scale bars A, 0.2 mm; inset, 50 ⁇ m; B, 20 ⁇ m; C, 10 ⁇ m; D, 5 ⁇ m; E, 2 ⁇ m.
- Tetanus toxin is a potent neurotoxin of 1315 amino acids that is produced by Clostridium tetani (1, 2). It prevents the inhibitory neurotransmitter release from spinal cord interneurons by a specific mechanism of cell intoxication (for review see ref 3). This pathological mechanism has been demonstrated to involve retrograde axonal and transynaptic transport of the tetanus toxin. The toxin is taken up by nerve endings at the neuromuscular junction, but does not act at this site; rather, the toxin is transported into a vesicular compartment and travels along motor axons for a considerable distance until it reaches its targets.
- transynaptic movement of tetanus toxin was first demonstrated by autoradiographic localization in spinal cord interneurons after injection into a muscle (4).
- previous studies of transynaptic passage of tetanus toxin from motoneurons were limited by the rapid development of clinical tetanus and death of the experimental animal (4, 5, 6).
- the fragment of tetanus toxin consists of a non-toxic proteolytic fragment of tetanus toxin (TT) comprising a fragment C and a fragment B or a fraction thereof of at least 11 amino acid residues or a non-toxic proteolytic fragment of tetanus toxin (TT) comprising a fragment C and a fragment B or a fraction thereof of at least 11 amino acids residues and a fraction of a fragment A devoid of its toxic activity corresponding to the proteolytic domain having a zinc-binding motif located in the central part of the chain between the amino acids 225 and 245 (cf. Montecucco C. and Schiavo G. Q. Rev.
- TT non-toxic proteolytic fragment of tetanus toxin
- fraction of the fragment A comprises, for example, the amino acid sequence 1 to 225 or the amino acid sequence 245 to 457, or the amino acid sequence 1 to 225 associated with amino acid sequence 245 to 457.
- the molecule having a biological function is selected from the group consisting of protein of interest, for example, for the compensation or the modulation of the functions under the control of the CNS or the spinal cord or the modulation of the functions in the CNS or the spinal cord, or protein of interest to be delivered by gene therapy expression system to the CNS or the spinal cord.
- the proteins of interest are, for example, the protein SMN implicated in spinal muscular atrophy (Lefebvre et al., Cell, (1995), 80:155-165 and Roy et al., Cell, (1955), 80:167-178); neurotrophic factors, such as BDNF (Brain-derived neurotrophic factor); NT-3 (Neurotrophin-3); NT-4/5; GDNF (Glial cell-line-derived neurotrophic factor); IGF (Insulin-like growth factor) (Oppenheim, Neuron, (1996), 17:195-197; Thoenen et al., Exp. Neurol., (1933), 124:47-55 and Henderson et al., Adv.
- BDNF Brain-derived neurotrophic factor
- NT-3 Neurotrophin-3
- NT-4/5 GDNF (Glial cell-line-derived neurotrophic factor)
- IGF Insulin-like growth factor
- PNI protease inhibitor 1
- SPI3 serine protease inhibitor protein
- ICE Interleukin-1 ⁇ converting Enzyme
- association means an association obtained by genetic recombination. This association can be realized upstream as well as downstream to the TT fragment.
- the preferred mode of realization of the invention is upstream and is described in detail; a downstream realization is also contemplated. (Despite Halpern et al., J. Biol. Chem., (1993), 268(15):11188-11192, who indicated that the carboxyl-terminal amino acids contain the domain required for binding to purified gangliosides and neuronal cells.)
- the desired CNS area means, for example, the tongue which is chosen to direct the transport to hypoglossal motoneuron; the arm muscle which is chosen to direct the transport to the spinal cord motoneurons.
- nucleotides may be introduced by transfection in vitro before reimplantation in area of the CNS or the spinal cord.
- a chemical linkage is considered for a particular embodiment of the invention and comprises the association between the TT fragment and a polynucleotide encoding the molecule of interest with its regulatory elements, such as promoter and enhancer capable of expressing said polynucleotide. Then the TT fragment allows the retrograde axonal transport and/or the transynaptic transport, and the product of the polynucleotide is expressed directly in the neurons.
- This chemical linkage can be covalent or not, but preferably covalent performed by thiolation reaction or by any other binding reaction as described in “Bioconjugate Techniques” from Gret T. Hermanson (Academic press, 1996).
- the axonal retrograde transport begins at the muscle level, where the composition of interest is taken up at the neuromuscular junction, and migrates to the neuronal body of the motoneurons (which are also called the first order neurons) in the CNS or spinal cord.
- motoneurons which are also called the first order neurons
- First order neurons mean neurons that have internalized the composition of interest, and thus in this case, correspond to motoneurons.
- the transynaptic retrograde transport corresponds to interneuron communications via the synapses from the motoneurons, and comprises second order neurons and higher order neurons (fourth order corresponding to neurons in the cerebral cortex).
- the different stages of the neuronal transport are through the neuromuscular junction, the motoneuron, also called first order neuron, the synapse at any stage between the neurons of different order, neuron of order second to fourth order, which corresponds to the cerebral cortex.
- a ⁇ -gal-TTC (TT-fragment C) hybrid protein retains the biological activities of both proteins in vivo. Therefore, the hybrid protein can undergo retrograde and transneuronal transport through a chain of interconnected neurons, as traced by its enzymatic activity. These results are consistent with those of others who used chemically conjugated TTC, or TTC fused to other proteins (12, 13, 14, 15). In these in vitro analyses, the activity of the conjugated or hybrid proteins was likewise retained or only weakly diminished. Depending on the nature of the TTC fusion partner, different types of potential applications can be envisioned. For example, this application can be used to deliver a biologically active protein into the CNS for therapeutic purposes. Such hybrid genes can also be used to analyze and map synaptically connected neurons if reporters; such as lacZ or the green fluorescent protein (GFP; 29) gene, were fused to TTC.
- reporters such as lacZ or the green fluorescent protein (GFP; 29) gene
- the retrograde transport of the hybrid protein may be demonstrated as follows. When injected into a muscle, ⁇ -gal activity rapidly localized to the somata of motoneurons that innervate the muscle. The arborization of the whole nerve, axon, somata and dendrites can easily be visualized. However, in comparison to the neurotropic viruses, the extent of retrograde transneuronal transport of the hybrid protein from the hypoglossal neurons indicates that only a subset of interconnected neurons is detected, although most areas containing second-order interneurons have been identified by the ⁇ -gal-TTC marker. Transneuronal uptake is mostly restricted to second order neurons.
- the transneuronal transport of the hybrid protein might depend on a synaptic specificity, although the tetanus toxin is not known to display any (7, 23). It is therefore likely that a virus would cross different or inactive synapses.
- the restricted spectrum of interneuronal transport in addition to its non-toxicity, make the ⁇ -gal-TTC hybrid protein a novel and powerful tool for analysis of neural pathways.
- fusion gene of the invention for neuronal mapping is that it derives from a single genetic entity that is amenable to genetic manipulation and engineering.
- a technique based on homologous recombination in embryonic stem cells was developed to specifically replace genes in the mouse (31, 32). This method generates a null mutation in the substituted gene, although in a slightly modified strategy, a dicistronic messenger RNA can also be produced (33, 34).
- a reporter gene such as E. coli lacZ
- this technique provides a means of marking the mutated cells so that they can be followed during embryogenesis.
- this technique greatly simplifies the analysis of both the heterozygote expression of the targeted gene as well as the phenotype of null (homozygous) mutant animals.
- the composition comprising the fusion gene may encode an antigen or antigens.
- the composition may be used to elicit an immune response in its host and subsequently confer protection of the host against the antigen or antigens expressed.
- immunization methods are described in Robinson et al., U.S. Pat. No. 5,43,578, which is herein incorporated by reference.
- the method of immunizing a patient or animal host comprises introducing a DNA transcription unit encoding comprising the fusion gene of this invention, which encodes a desired antigen or antigens. The uptake of the DNA transcription unit by the host results in the expression of the desired antigen or antigens and the subsequent elicitation of humoral and/or cell-mediated immune responses.
- Another extension of the invention is to gene therapy applied to the CNS.
- This invention provides for uptake of a non-toxic, enzyme-vector conjugate by axon terminals and conveyance retrogradely to brainstem motoneurons.
- a selective retrograde transynaptic mechanism subsequently transports the hybrid protein into second-order connected neurons.
- Such a pathway which by-passes the blood-brain barrier, can deliver macromolecules to the CNS.
- pathogenic agents such as tetanus toxin and neurotropic viruses, are similarly taken up by nerve endings, internalized, and retrogradely transported to the nerve cell somata.
- the lacZ reporter would be replaced by a gene encoding a protein that provides a necessary or interesting activity and/or function.
- the human CuZn superoxide dismutase, SOD-1, and the human enzyme ⁇ -N-acetylhexosaminidase A, HexA have been fused or chemically coupled to the TTC fragment (13, 16), and their uptake by neurons in vitro was considerably increased and their enzymatic functions partially conserved.
- a gene therapy approach based on TTC hybrid proteins appears to be a feasible method of delivering a biological function to the CNS.
- ways have to be found to target the TTC hybrid proteins, which are likely to be sequestrated into vesicles, to the appropriate subcellular compartment.
- Such a therapeutic strategy could be particularly useful for treating neurodegenerative and motoneuron diseases, such as amyotrophy lateral sclerosis (ALS, 35), spinal muscular atrophies (SMA, 36, 37), or neurodegenerative lysosomal storage diseases (38, 39). Injection into selected muscles, even in utero, could help to specifically target the appropriate neurons. In addition, such an approach would avoid the secondary and potentially toxic effects associated with the use of defective viruses to deliver a gene (40, 41).
- ALS amyotrophy lateral sclerosis
- SMA spinal muscular atrophies
- 38, 39 neurodegenerative lysosomal storage diseases
- PCR1 of 465 bp (primer 1: 5′-CCC CCC GGG CCA CCA TGG TTT TTT CAA CAC CM TTC CAT TTT CTT ATT C-3′ (SEQ ID NO:4) and primer 2: 5′-CTA MC CAG TM TTT CTG-3′ (SEQ ID NO:5)
- PCR2 of 648 bp (primer 3: 5′-MT TAT GGA CTT TM MG ATT CCG C-3′ (SEQ ID NO:6) and primer 4: 5′-GGC ATT ATA ACC TAC TCT TAG MT-3′ (SEQ ID NO:7)
- PCR3 of 338 bp (primer 5: 5′-AAT GCC TTT MT MT CTT GAT AGA MT-3′ (SEQ ID NO:4)
- the three fragments were sequentially introduced into pBluescript KS+ (Stratagene) to give pBS:TTC plasmid.
- the upstream primer 1 also contains an optimized eukaryotic Ribosome Binding Site (RBS) and translational initiation signals.
- Our TTC fragment (462 amino acids) represents the amino acids 854-1315 of tetanus holotoxin, i.e. the carboxy-terminal 451 amino acids of the heavy chain, which constitute the fragment C plus 11 amino acids of the heavy chain that immediately precede the amino terminus of the fragment C.
- the DNA sequence and amino acid sequence of the TTC fragment cloned in pBS:TTC is shown in FIG. 1 .
- the construct pBS:TTC is shown in FIG. 2 .
- pGEX:lacZ was obtained by cloning a SmaI/XhoI lacZ fragment from the pGNA vector (a gift from Dr. H. Le Mouellic) into pGEX 4T-2 (Pharmacia). PCR was used to convert the lacZ stop codon into an NcoI restriction site.
- Two primers upstream: 5′-CTG MT ATC GAC GGT TTC CAT ATG-3′ (SEQ ID NO:10) and downstream: 5′-GGC AGT CTC GAG TCT AGA CCA TGG CTT TTT GAC ACC AGA C-3′ (SEQ ID NO:11)) were used to amplify the sequence between NdeI and XhoI, generating pGEX:lacZ(NcoI) from pGEX:lacZ.
- pGEX:lacZ-TTC was obtained by insertion of the TTC NcoI/XhoI fragment into pGEX:lacZ(NcoI), fusing TTC immediately downstream of the lacZ coding region and in the same reading frame.
- FIG. 3 shows the details of the pGEX:lacZ-TTC construct.
- pBS:TTC was modified to change NcoI into a BamHI restriction site (linker 5′-CAT GAC TGG GGA TCC CCA GT-3′ (SEQ ID NO:12)) at the start of the TTC DNA, to give pBS:TTC(BamHI) plasmid.
- pGEX:TTC was obtained by cloning The TTC BamHI/SmaI fragment from pBS:TTC(BamHI) into pGEX 4T-2 (Pharmacia) PCR was used to convert the TTC stop codon into an NheI restriction site.
- Two primers upstream: 5′-TAT GAT AAA AAT GCA TCT TrA GGA-3′ (SEQ ID NO:13) and downstream: 5′-TGG AGT CGA CGC TAG CAG GAT CAT TTG TCC ATC CTT C-3′ (SEQ ID NO:14)) were used to amplify the sequence between NsiI and SmaI, generating pGEX:TTC(NheI) from pGEX:TTC.
- the lacZ cDNA from plasmid pGNA was modified in its 5′ extremity to change SacII into an NheI restriction site (linker 5′-GCT AGC GC-3′ (SEQ ID NO:15)).
- pGEX:TTC-lacZ was obtained by insertion of the lacZ NheI/XhoI fragment into pGEX:TTC(NheI), fusing lacZ immediately downstream of the TTC coding region and in the same reading frame.
- the details of the construct of pGEX:TTC-lacZ are shown in FIG. 4 .
- pCMV vector was obtained from pGFP-C1 (Clontech laboratories) after some modifications: GFP sequence was deleted by a BgIII/NheI digestion and relegation, and SacII in the polylinker was converted into an AscI restriction site (linkers 5′-GATATC GGC GCG CCA GC-3′ (SEQ ID NO:16) and 5′-TGG CGC GCC GAT ATC GC-3′ (SEQ ID NO:17)).
- pBluescript KS+ (Stratagene) was modified to change XhoI into an AscI restriction site (linker 5′-TCG ATG GCG CGC CA-3′ (SEQ ID NO:18)), giving pBS(AscI) plasmid.
- pBS:lacZ-TTC was obtained by cloning a XmaI lacZ-TTC fragment from pGEX:lacZ-TTC into pBS(AscI).
- pCMV:lacZ-TTC was obtained by insertion of the lacZ-TTC XmnI/AscI fragment into pCMV vector at the XhoI and AscI sites (XhoI and XmnI was eliminated with the clonage), putting the fusion downstream of the CMV promotor.
- FIG. 8 shows the details of the construct pCMV:lacZ-TTC. Plasmid pCMV:lacZ-TTC was deposited on Aug. 12, 1997, at the Collection Nationale de Cultures de Microorganisms (CNCM), institut Pasteur, 25, Rue de Do Frankfurt Roux, F-75724, Paris Cedex 15, France, under Accession No. 1-1912.
- the E. coli strain SR3315 (a gift from Dr. A. Pugsley, Institut Pasteur) transfected with pGEX:lacz-TTC was used for protein production.
- An overnight bacterial culture was diluted 1:100 in LB medium containing 100 ⁇ g/ml ampicillin, and grown for several hours at 32° C. until an OD of 0.5 was reached.
- Induction from the Ptac promoter was achieved by the addition of 1 mM IPTG and 1 mM MgCl 2 and a further 2 hrs incubation.
- the induced bacteria were pelleted by centrifugation for 20 min at 3000 rpm, washed with PBS and resuspended in lysis buffer containing 0.1M Tris pH 7.8, 0.1M NaCl, 20% glycerol, 10 mM EDTA, 0.1% Triton-X100, 4 mM DTT, 1 mg/ml lysosyme, and a mixture of anti-proteases (100 ⁇ g/ml Pefablok, 1 ⁇ g/ml leupeptin, 1 ⁇ g/ml pepstatin, 1 mM benzamidine). After cell disruption in a French Press, total bacterial lysate was centrifuged for 10 min at 30000 rpm.
- the resulting supernatant was incubated overnight at 4° C. with the affinity matrix Glutathione Sepharose 4B (Stratagene) with slow agitation. After centrifugation for 5 min at 3000 rpm, the matrix was washed three times with the same lysis buffer but without lysosyme and glycerol, and then three times with PBS. The resin was incubated overnight at 4° C. with Thrombin (10 U/ml; Sigma) in PBS in order to cleave the ⁇ -gal-TTC fusion protein from the Glutatione-S-transferase (GST) sequence and thereby elute it from the affinity column. Concentration of the eluted fusion protein was achieved by centrifugation in centricon X-100 tubes (Amicon; 100,000MW cutoff membrane).
- Purified hybrid protein was analyzed by Western blotting after electrophoretic separation in 8% acrylamide SDS/PAGE under reducing conditions followed by electrophoretic transfer onto nitrocellulose membranes (0.2 mm porosity, BioRad). Immunodetection of blotted proteins was performed with a Vectastaln ABC-alkaline phosphatase kit (Vector Laboratories) and DAB color development. Antibodies were used as follows: rabbit anti- ⁇ -gal antisera (Capel), dilution 1:1000; rabbit anti-TTC antisera (Calbiochem), dilution 1:20000. A major band with a relative molecular mass of 180 kDa corresponding to the ⁇ -Gal-TTC hybrid protein was detected with both anti- ⁇ -Gal anti-TTC antibodies.
- the 1009 cell line was derived from a spontaneous testicular teratocarcinoma arising in a recombinant inbred mouse strain (129 ⁇ B6) (17).
- the 1009 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum and passaged at subconfluence.
- DMEM Dulbecco's modified Eagle's medium
- In vitro differentiation with retinoic acid and cAMP was performed as described (18). Eight days after retinoic acid treatment, cells were used for the internalization experiments with either the hybrid protein or ⁇ -gal.
- Binding and internalization of the ⁇ -Gal-TTC fusion were assessed using a modified protocol (16). Differentiated 1009 cells were incubated for 2 hrs at 37° C. with 5 ⁇ g/ml of ⁇ -Gal-TTC or ⁇ -Gal protein diluted in binding buffer (0.25% sucrose, 20 mM Tris acetate 1 mM CaCl 2 , 1 mM MgCl 2 , 0.25% bovine serum albumin, in PBS).
- binding buffer 0.25% sucrose, 20 mM Tris acetate 1 mM CaCl 2 , 1 mM MgCl 2 , 0.25% bovine serum albumin, in PBS.
- the cells were then incubated with 1 ⁇ g/ml Pronase E (Sigma) in PBS for 10 min at 37° C., followed by washing with proteases inhibitors diluted in PBS (100 ⁇ g/ml Pefablok, 1 mM benzamidine).
- the cells were fixed with 4% formalin in PBS for 10 min at room temperature (RT) and then washed extensively with PBS. ⁇ -gal activity was detected on fixed cells by an overnight staining at 37° C. in X-Gal solution (0.8 mg/ml X-Gal, 4 mM potassium ferricyanide, 4 mM potassium ferrocyanide, 4 mM MgCl 2 in PBS). For electron microscopy, the cells were further fixed in 2.5% glutaraldehyde for 18 hrs, and then-processed as described (19).
- the labeling was visualized using fluorescent secondary antibodies: Cy3, goat anti-rabbit IgG (dilution 1:500; Amersham) or anti-mouse IgG with extravidin-FITC (dilution 1:200; Sigma). Cells were mounted in moviol and visualized with epifluorescence.
- mice 14-week old B6D2 ⁇ l mice were obtained from IFFA-CREDO.
- the animal's tongue muscle was injected using an Hamilton syringe (20 ⁇ l per animal) while under general anesthesia with 3% Avertin (15 ⁇ l/g of animal).
- the protein concentration was 0.5 to 5 ⁇ g/ ⁇ l in PBS; therefore, mice received approximately 10 to 100 ⁇ g per injection.
- Animals were kept alive for 12 hrs to 48 hrs post-injection to permit migration of the injected protein, and in no case were any tetanus symptoms detected.
- the mice were sacrificed by intracardiac perfusion with 4% paraformaldehyde in PBS while under deep anesthesia. Brains were harvested, rinsed in PBS and incubated in 15% sucrose overnight at 4° C., then mounted in tissue-tek before sectioning, 15 ⁇ m thick slices using a cryostat.
- mice (10 animals) were sacrificed and fixed as described above.
- the brain was further cut with a scalpel along a median plane and directly incubated for 12 hrs in X-Gal solution.
- X-Gal staining or immunolabeling were performed after incubation with the ⁇ -gal-TTC fusion protein or with either the ⁇ -gal or TTC proteins alone. Only when the hybrid protein was incubated with differentiated 1009 cells was a strong X-Gal staining detected in cells having a neuronal phenotype. No signal was detected when ⁇ -gal alone was incubated under the same conditions. A similar X-Gal staining pattern was obtained after pronase treatment of the cells to remove surface bound proteins, indicating that the hybrid protein had been internalized.
- the intracellular localization of the hybrid protein was further confirmed by electron microscopic analysis of X-Gal-stained cells. Furthermore, the enzymatic activity observed in axons seemed to be localized in vesicles associated with filaments, which is in agreement with previous work on TTC fragment or native tetanus toxin (14, 21, 22). Co-labeling with anti-TTC and anti-neurofilament antibodies revealed that ⁇ -gal activity co-localized with TTC fragment in neuronal cells. No glial cells were labeled with either antibody.
- the hybrid protein was tested in a well characterized neuronal network, the hypoglossal system.
- the distribution of the hybrid protein in the CNS was analyzed by X-Gal staining.
- Various dilutions of the protein were injected and sequential time points were analyzed to permit protein transport into hypoglossal motoneurons (XII), and its further transneuronal migration into connected second order neurons.
- WGA-HRP wheat germ agglutinin-horseradish peroxidase complex
- AZA-HRP neurotropic viruses
- alpha-herpes (24) and rhabdoviruses 25.
- the distribution of the ⁇ -gal-TTC fusion depended on the initial concentration of protein injected into the muscle and the time allowed for transport after injection. Up to 24 hrs post-injection, labeling was restricted to the hypoglossal nuclei.
- LRF lateral reticular formation
- MdD medullary reticular dorsal
- MdV medullary reticular ventral
- This column extends rostrally through the medulla, with neurons more intensely labeled in the parvicellular reticular nucleus (PCRt, caudal and rostral). After 48 hrs, cells in MdD and PCRt were more intensely stained. A second bilateral distribution of medullary neurons projecting to the hypoglossal nucleus was detected in the solitary nucleus (Sol) but the labeling was less intense than in the reticular formation, presumably because relatively few cells of the solitary nucleus project onto the hypoglossal nucleus (26). However, no labeling was found in the spinal trigeminal nucleus (Sp5), which has also been shown to project onto the hypoglossal nucleus (26).
- Transynaptic transport of the ⁇ -gal-TTC protein was also detected in the pontine reticular nucleus caudal (PnC), the locus coeruleus (LC), the medial vestibular nucleus (MVe) and in a few cells of the inferior vestibular nucleus (IV).
- PnC pontine reticular nucleus caudal
- LC locus coeruleus
- MVe medial vestibular nucleus
- IV inferior vestibular nucleus
- DPGi the magnocellular nucleus caudal (RMc), and the caudal raphe nucleus (R); their connections to the hypoglossal nucleus have also been reported (25).
- labeled neurons were detected bilaterally in midbrain projections, such as those of the mesencephalic trigeminal nucleus (Me5), and a few neurons were stained in the mesencephalic central gray region (CG). These latter nuclei have been typed as putative third order cell groups related to the hypoglossal nucleus (25).
- Neurons in the motor trigeminal nucleus (Mo5) and the accessory trigeminal tract (Acs5) were also labeled, along with a population of neurons in the facial nucleus (N7).
- interpretation of this labeling is more ambiguous, since it is known that motoneurons in these nuclei also innervate other parts of the muscular tissue, and diffusion of the hybrid protein might have occurred at the point of injection.
- these nuclei may have also projected to the tongue musculature via nerve XII, since neurons in N7 have been reported to receive direct hypoglossal nerve input (28). This latter explanation is consistent with the fact that labeling in these nuclei was detected only after 24 hrs; however, this point was not further investigated.
- Second order cell groups MdD, medullary reticular nu, dorsal ⁇ ++ MdV, medullary reticular nu, ventral ⁇ +/ ⁇ PCRt, parvicellular reticular nu, caudal ⁇ ++ PCRt, parvicellular reticular nu, rostral ⁇ ++ Sol, solitary tract nu ⁇ + DPGi, dorsal paragigantocellular nu ⁇ +/ ⁇ PnC, pontine reticular nu, caudal ⁇ + RMc, magnocellular reticular nu ⁇ +/ ⁇ R, caudal raphe nu ⁇ +/ ⁇ MVe, medial vestibular nu ⁇ + IV, inferior vestibular nu ⁇ +
- GFP-TTC fusion protein
- the GFP-TTC fusion protein permits the visualization of membrane traffic at the presynaptic level of the neuromuscular junction and can be detected opticaly without immunological or enzymatic reactions.
- the GFP-TTC fusion protein therefore, permits observation of active neurons with minimal disturbance of their physiological activities.
- GFP-TRC GFP-TRC
- BDNF Brain Derivated Neurotrophic Factor
- NT-4 Neurotrophin 4
- GDNF Glial-Derived Neurotrophic Factor
- NGF Nerve Growth Factor
- NT-3 Neurotrophin 3
- CNTF Ciliary Neurotrophic Factor
- BDNF neuromuscular junction
- BDNF might increase GFP-TTC internalization through enhancement of synaptic vesicle turnover.
- BoTx/A treatment blocks exocytosis and endocytosis of synaptic vesicles, showing that BDNF increases the kinetics and localization of a TTC-containing fusion protein at the NMJ through another endocytic pathway.
- GFP-TTC intramuscular injection of GFP-TTC and visualization of transport mechanisms revealed at least two different endocytic pathways: a clathrin-dependent and a clathrin-independant pathways.
- a clathrin-dependent pathway displayed characteristics consistent with localization in lipid rafts, including biochemical colocalization with caveolin 3 and colocalization with GM1, a raft marker identified by CT-b binding (Orlandi and Fishman, 1998; Wolf et al., 1998).
- the clathrin-independent pathway used by GFP-TTC appears to involve lipid microdomains. Analysis by confocal microscopy revealed morphologically two different labelings.
- a GFP-TTC diffuse staining which partially overlaps with the synaptic vesicle SV2 but also with the raft marker CT-b, indicating a mixing of synaptic vesicles and lipid rafts.
- highly fluorescent domains which are detected before and persist after the more diffuse pattern and that appear to be invaginations or infoldings of the synaptic membrane.
- These GFP-TTC patches contained only CT-b labeling. Indeed, lipid microdomains which play a role in cellular functions such as vesicular trafficking and signal transduction (Simons and Toomre, 2000), can move laterally and cluster into larger patches (Harder et al., 1998).
- the difference we observed in the dynamics of recruitment at the presynaptic motor nerve terminal may be relevant to different lipid microdomains having specific glycosphingolipids and protein composition.
- Neuronal membranes are rich in gangliosides and different microdomains are likely to co-exist on the cell surface.
- Thy-1 and PrP prion protein two functionally different GPI proteins, are found in adjacent microdomains (Madore et al., 1999).
- syntaxins are concentrated in cholesterol-dependent microdomains, which are distinct from rafts containing GPI-linked proteins (Lang et al., 2001).
- TrkB was also found to increase the concentration of GFP-TTC at the NMJ, whereas NGF and NT-3 had no effect. Since the TrkB receptor is specifically activated by BDNF and NT4, TrkB activation might be involved in this neoronal trafficking. Interestingly, high-frequency neuronal activity and synaptic transmission have been shown to elevate the number of TrkB receptors on the surface of cultured hippocampal neurons (Du et al., 2000), apparently by recruiting extra TrkB receptors to the plasma membrane (Meyer-Franke et al., 1998). Moreover, TrkB is highly enriched in lipid microdomains from neuronal plasma membrane (Wu et al., 1997). However, no specific colocalization between GFP-TTC and TrkB or p-Trk receptors were detected at the NMJ. Thus, TrkB may act indirectly on the detected traffic at the presynaptic motor nerve membrane.
- TTC fragment has been detected in cultured motoneurons in the same vesicles as p75 NTR (Lalli and Schiavo, 2002). This colocalization may be explained by the tight association of p75 NTR , which is expressed mainly during development and in pathological conditions, with GT1b ganglioside (Yamashita et al., 2002). Binding of neurotrophins to their Trk receptors leads to phosphorylation of tyrosine residues that are recognized by several intracellular signaling proteins.
- the coreceptor GFR ⁇ 1 which binds GDNF and thus allows activation of the c-RET tyrosine kinase receptor, localize to lipid rafts. GFR ⁇ 1 recruits RET to lipid rafts after GDNF stimulation and results in strong and continuous signal transduction (Paratcha et al., 2001; Tansey et al., 2000).
- GDNF Another neurotrophic factor, GDNF, also induced GFP-TTC localization at the NMJ.
- GDNF activates a different receptor (i.e., a GFR ⁇ /cRET receptor) than BDNF and NT4.
- BDNF/NT-4 and GDNF activate different receptors, we postulated that component(s) of their activation pathways may activate the trafficking of GFP-TTC receptors in specific lipid microdomains.
- various stimuli can lead to internalization of caveolae, a specialized form of lipid rafts.
- simian virus 40 stimulates its internalization in caveolae and transport via caveosomes (Pelkmans et al., 2001).
- the albumin-docking protein pg60 activates its transendothelial transport by interaction with caveolin-1 and subsequent activation of Src kinase signaling (Minshall et al., 2000). Recently, it has been reported that tetanus toxin can activate, through the TTC fragment, intracellular pathways involving Trk receptors, extracellular signal-regulated kinases (ERK) and protein kinase C isoforms (Gil et al., 2001; Gil et al., 2000; Gil et al., 2003). In this way, tetanus toxin could therefore autoactivate its neuronal endocytosis via an uncoated pathway rather than by clathrin-dependent pathway to avoid the lysosomal degradation.
- ERK extracellular signal-regulated kinases
- GFP-TTC trafficking is regulated by neurotrophic factors.
- BDNF can stimulate both clathrin-coated and uncoated endocytic pathways, presumably via TrkB activation. Since tetanus toxin, as other pathogens or toxins, uses constitutive mechanisms for its internalization and traffic in cells, we have been able to visualize with GFP-TTC, a physiological response to neurotrophic factors.
- LAL Levator auris longus
- GFP-TTC rapidly concentrates at the NMJ, as identified by the staining of muscle nicotinic acetylcholine receptors with TRITC-conjugated ⁇ -bungarotoxine ( ⁇ -BTX).
- ⁇ -BTX TRITC-conjugated ⁇ -bungarotoxine
- TrkB mutant mice a physiological phenotype in the facial nerve nucleus, which innervates LAL muscle has been reported (Klein et al., 1993; Silas-Santiago et al., 1997).
- GFP-TTC ⁇ BDNF 50 ng
- muscles were fixed, removed and serially sectioned.
- different serial sections were quantified for GFP-TTC fluorescence at the motor nerve terminals as described in material and methods.
- TrkB mRNA or protein in adult skeletal muscle and motoneurons has been reported in several studies (Funakoshi et al., 1993; Gonzalez et al., 1999; Griesbeck et al., 1995; Yan et al., 1997). Since our results indicated that the BDNF effect on GFP-TTC localization is dependent on TrkB receptor activation, it was of interest to determine whether GFP-TTC colocalized with TrkB at the NMJ of LAL muscles. Consistent with previous studies (Gonzalez et al., 1999; Sakuma et al., 2001), TrkB immunostaining was confined to the NMJ ( FIG. 8 ).
- TrkB staining was adjacent to, but not colocalized to the clusters of GFP-TTC labeling. Similar results were also obtained with an antibody that recognizes the activated Trk receptors (p-Trk, data not shown). This observation suggests that the mechanism whereby BDNF has an influence on the concentration of GFP-TTC at the nerve terminals, does not involve a direct interaction between TrkB and GFP-TTC or its receptors.
- BoTx/A botulinum neurotoxin serotype A
- Enhanced synaptic transmission produced by application of exogenous BDNF; NT-3 or NT4 involves a potentiation of neurotransmitter release (Lohof et al., 1993; Stoop and Poo, 1996; Wang and Poo, 1997).
- the increasing amount of GFP-TTC at the NMJ induced by BDNF injection could therefore be due in part to an elevated recycling of synaptic vesicles.
- increased exocytosis and endocytosis of synaptic vesicles were induced by GFP-TTC injection in a high-potassium medium. Five minutes after injection, exposure to high K + medium or BDNF induced a similar increase of GFP-TTC level at the NMJ.
- TTC Binding of TTC to plasma membranes involves association to polysialogangliosides GD1 b and GT1b, as well as a N-glycosylated 15 kDa protein. These three components partition preferentially in membrane microdomains called rafts.
- TTC has been shown to associate with such microdomains in NGF-differentiated PC12 cells and in cultured spinal cord neurons (Herreros et al., 2001 Vyas, 2001).
- GFP-TTC associated to lipid rafts gastrocnemius muscles were submitted to detergent extraction to isolate lipid microdomains after GFP-TTC intramuscular injection. Twelve fractions from the discontinuous sucrose gradient were collected and analyzed for distribution of GFP-TTC.
- CT-b specifically binds to ganglioside GM1, which is enriched in cholesterol-rich membrane microdomains, and is commonly used as a marker for membrane rafts and caveolae (Orlandi and Fishman, 1998; Schnitzer et al., 1995; Wolf et al., 1998).
- Rabbit anti-GFP polyclonal antibodies was obtained from Invitrogen (1:5000 dilution). Mouse monoclonal antibody against caveolin 3 was from Transduction Laboratories (1:500). The monoclonal anti-neurofilament 200 (clone NE14) and the rabbit polyclonal antitroponin T were obtained from Sigma. AlexaFluor 594-conjugated Cholera toxin subunit B (CT-b); AlexaFluor 488-conjugated goat-antirabbit IgG, AlexaFluor 647-conjugated ⁇ -bungarotoxin ( ⁇ -BTX) and RH414 were obtained from Molecular Probes.
- Cy3-conjugated goat anti-rabbit IgG and Cy3-conjugated rat anti-mouse IgG were from Jackson Laboratories.
- TRITC-conjugated ⁇ -bungarotoxin was obtained from Calbiochem.
- the rabbit anti-TrkB (794) and the anti-p-Trk polyclonal antibody were obtained from SantaCruz.
- Monoclonal antibody against synaptic vesicle synaptophysin protein was obtained from Chemicon.
- the goat anti-rabbit and anti-mouse IgG antibodies conjugated to horseradish peroxydase were obtained from Pierce as well as the SuperSignal detection reagent.
- Recombinant neurotrophic factors rat CNTF; human NT3; human NT4, human BDNF, human GDNF and purified mouse NGF 7S were purchased from Alomone labs. Neurotrophic factors were prepared as stock solutions (10 ⁇ g/ml) and kept in aliquots at ⁇ 80° C.
- GFP-TTC probe For immunodetection or biochemical extraction, 50 ⁇ g of GFP-TTC probe were used. When co-injections with neurotrophic factors were performed, the volume injected was kept constant (50 ⁇ l). For injection in high K + , a physiological solution containing 60 mM KCl was co-injected with the probe.
- Clostridium botulinum type-A toxin (BoTx/A) was injected subcutaneously as a single dose of 0.05 ml containing about 0.5 pg of the purified neurotoxin in the vicinity of the LAL muscle of female Swiss mice (body weight 24-27 g).
- BoTx/A a time sufficient for inducing muscle paralysis in the LAL due to blockade of neurotransmitter release (de Paiva et al., 1999)
- GFP-TTC 25 ⁇ g
- mice were killed by intracardial injection of PFA 4% 30 min after injection and LAL muscle harvested and processed for confocal analysis.
- mM mM
- Muscles were loaded for 45 min in the dark and at room temperature with both 25 ⁇ g GFP-TTC and 30 ⁇ M of RH414, dissolved in standard solution or, for synaptic vesicle recycling, in high K + isotonic solution (with 60 mM KCl replacing 60 mM NaCl). Preparations were washed out of the GFP-TTC and RH414 dye, and rinsed several times with dye-free standard medium before being imaged with a Leica TCS SP2 confocal laser scanning microscope system (Leica Microsystems, Germany) mounted on a Leica DM-RXA2 upright microscope equipped with a x40 water immersion lens (Leica, NA 0.8). The confocal system was controlled through Leica-supplied software running on a Windows NT workstation.
- Preparation of detergent-resistant membrane fractions is one of the most widely used methods for studying lipid rafts.
- Two hours after GFP-TTC injection (50 ⁇ g) mouse gastrocnemius muscle tissue was harvested, minced with scissors and homogenized in 2 ml of MES-buffered saline containing 1% (v/v) Triton X-100. Homogenization was carried out with a Polytron tissue grinder. After centrifugation at low speed for 5 min, supernatant was adjusted to 40% sucrose. A 5-30% linear sucrose gradient was formed above the homogenate and centrifuged at 39,000 rpm for 18 h in a SW41 rotor.
- TRITC-a-BTX TRITC-conjugated a-bungarotoxin
- mice deeply anesthetized were perfused intracardially with 4% PFA.
- the spinal cord was harvested and embedded in Tissue Tek embedding media after overnight incubation in 25% sucrose in PBS 0.1M. Longitudinal cryostat sections (30 ⁇ m thickness) were cut and mounted onto coated slides.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Description
- This invention relates to the use of part of tetanus toxin for delivering a composition to the central nervous system of a human or animal. This invention also relates to a hybrid fragment of tetanus toxin, a polynucleotide that hybridizes with natural tetanus toxin, and a composition containing the tetanus toxin fragment as an active molecule. Further, this invention relates to a vector comprising a promoter and a nucleic acid sequence encoding the tetanus toxin fragment.
- Tetanus toxin is produced by Clostridium tetani as an inactive, single, polypeptide chain of 150 kD composed of three 50 kD domains connected by protease-sensitive loops. The toxin is activated upon selective proteolytic cleavage, which generates two disulfide-linked chains: L (light, 50 kD) and H (heavy, 100 kD) [Montecucco C. and Schiavo G. Q. Rev. Biophys., (1995), 28:423-472].
- Evidence for the retrograde axonal transport of tetanus toxin to central nervous system (CNS) has been described by Erdmann et al. [Naunyn Schmiedebergs Arch Phamacol., (1975), 290:357-373], Price et al. [Science, (1975), 188:945-94], and Stoeckel et al. [Brain Res., (1975), 99:1-16]. In each of these studies, radiolabeled toxin was found inside membrane bound vesicles. Another property was the transynaptic movement of tetanus toxin that was demonstrated first by autoradiographic localization of 125I-labeled tetanus toxin in spinal cord interneurons after injection into a muscle [Schwab and Thoenen, Brain Res., (1976), 105:218-227].
- The structure of this tetanus toxin has been elucidated by Helting et al. [J. Biol. Chem., (1977), 252:187-193]. Papain cleaves the tetanus toxin in two fragments:
- the C terminal part of the heavy chain, 451 amino acids, also called fragment C; and
- the other part contained the complementary portion called fragment B linked to the light chain (fragment A) via a disulfide bond.
- European Patent No.
EP 0 030 496B1 showed the retrograde transport of a fragment B-IIb to the CNS and was detected after injection in the median muscle of the eye in primary and second order neurons. This fragment may consist of “isofragments” obtained by clostridial proteolysis. Later, this fragment B-IIb was demonstrated to be identical to fragment C obtained by papain digestion by Eisel et al. [EMBO J., 1986, 5:2495-2502]. - This EP patent also demonstrated the retrograde transport of a conjugate consisting of a Ibc tetanus toxin fragment coupled by a disulfide bond to B-IIb from axonal endings within the muscle to the motoneuronal perikarya and pericellular spaces. (The Ibc fragment corresponds to the other part obtained by papain digestion as described above by Helting et al.). There is no evidence that this conjugate was found in second order neurons. The authors indicated that a conjugate consisting of the fragment B-IIb coupled by a disulfide bond to a therapeutic agent was capable of specific fixation to gangliosides and synaptic membranes. No result showed any retrograde axonal transport or a transynaptic transport for such conjugate.
- Another European Patent, No.
EP 0 057 140 B1, showed equally the retrograde transport of a fragment IIc to the CNS. As in the European Patent No.EP 0 030 496 B1, the authors indicated that a conjugate consisting of the fragment IIc and a therapeutic agent was capable of specific fixation, but no result illustrated such allegation. This fragment IIc corresponds to the now called fragment C obtained by papain digestion. - Francis et al. [J. Biol. Chem., (1995), 270(25):15434-15442] led an in vitro study showing the internalization by neurons of hybrid between SOD-1 (Cu Zn superoxide dismutase) and a recombinant C tetanus toxin fragment by genetic recombination. This recombinant C tetanus toxin fragment was obtained from Halpern group. (See ref. 11).
- Moreover, Kuypers H. G. J. M and Ugolini G. [TINS, (1990), 13(2):71-75] indicated in their publication concerning viruses as transneuronal tracers that, despite the fact that tetanus toxin fragment binds to specific receptors on neuronal membranes, transneuronal labeling is relatively weak and can be detected only in some of the synaptically connected neurons.
- Notwithstanding these advances in the art, there still exists a need for methods for delivering compositions into the human or animal central nervous system. There also exists a need in the art for biological agents that can achieve this result.
- Additionally, activity-dependent modification of neuronal connectivity and synaptic plasticity play an important role in the development and function of the nervous system. Recently, much effort has been dedicated to following such modifications by the engineering of new optically detectable genetic tools. For example, fused to a reporter gene such as LacZ or GFP (Green Fluorescent Protein), the atoxic C-terminal fragment of tetanus toxin (or TTC fragment) can traffic retrogradely and transsynaptically inside a restricted neural network either after direct injection of the hybrid protein (Coen et al., 1997), or when expressed as a transgene in mice (Maskos et al., 2002). The dynamics of βgal-TTC clustering at the neuromuscular junction (NMJ) is strongly dependent on a presynaptic neuronal activity and probably involves fast endocytic pathways (Miana-Mena et al., 2002). Neuronal activity may induce this clustering and internalization at the NMJ by enhancing the secretion and/or action of various molecules at the synapse.
- Over the past decade, various data indicate that neurotrophins, a family of structurally and functionally related proteins, including NGF (Nerve Growth Factor); BDNF (Brain Derived Neurotrophic Factor); Neurotrophin 3 (NT-3) and Neurotrophin 4 (NT-4), not only promote neuronal survival and morphological differentiation, but also can acutely modify synaptic transmission and connectivity in central synapses, thus providing a connection between neuronal activity and synaptic plasticity (McAllister et al., 1999; Poo, 2001; Tao and Poo, 2001). The role of these factors in neurotransmission between motoneurons and skeletal muscle cells has been studied using Xenopus nerve-muscle co-culture studies, whereby the treatment of these cultures with exogenous BDNF, NT-3 or NT-4 leads to an increase of synaptic transmission by enhancing neurotransmitter secretion (Lohof et al., 1993; Stoop and Poo, 1996; Wang and Poo, 1997). Moreover, the muscular expression of NT-3 and NT-4 (Funakoshi et al., 1995; Xie et al., 1997), as well as NT-4 secretion (Wang and Poo, 1997) are regulated by electrical activity. This family of proteins thus provides a molecular link between electrical neuronal activity and synaptic changes.
- The cellular actions of neurotrophins are mediated by two types of receptors: the p75NTR receptor, mainly expressed during early neuronal development, and a Trk tyrosine kinase receptor (Bothwell, 1995). The interaction of neurotrophins with Trk receptors is specific. TrkB and TrkC, are activated by BDNF/NT-4 and NT-3, respectively, and are expressed by motor neurons. TrkA, which is expressed by sensory neurons, is activated by NGF. Recently, evidence for a co-trafficking between TTC and the neurotrophin receptor p75NTR has been reported in cultured motoneurons (Lalli and Schiavo, 2002), as well as the activation by tetanus toxin and the TTC fragment of intracellular pathways involving Trk receptors in cultured cortical neurons (Gil et al., 2003).
- Notwithstanding the knowledge in the art, there still exists a need for understanding the influences of neurotrophins and other neurotrophic factors on TTC traffic at the NMJ in vivo and for developing methods of using these neurotrophins and neurotrophic factors, and agonists or antagonists thereof, to modulate the neuronal transport of a tetanus toxin or a fusion protein comprising a fragment C of the tetanus toxin.
- This invention aids in fulfilling these needs in the art. More particularly, this invention provides a method for in vivo delivery of desired composition into the central nervous system (CNS) of the mammal, wherein the composition comprises a non-toxic proteolytic fragment of tetanus toxin (TT) in association with at least a molecule having a biological function. The composition is capable of in vivo retrograde transport and transynaptic transport into the CNS and of being delivered to different areas of the CNS.
- This invention also provides a hybrid fragment of tetanus toxin comprising fragment C and fragment B or a fraction thereof of at least 11 amino acid residues or a hybrid fragment of tetanus toxin comprising fragment C and fragment B or a fraction thereof of at least 11 amino acid residues and a fraction of fragment A devoid of its toxic activity corresponding to the proteolytic domain having a Zinc-binding motif located in the central part of the chain between the amino acids 225 and 245, capable of transferring in vivo a protein, a peptide, or a polynucleotide through a neuromuscular junction and at least one synapse.
- Further, this invention provides a composition comprising an active molecule in association with the hybrid fragment of tetanus toxin (TT) or a variant thereof. The composition is useful for the treatment of a patient or an animal affected with CNS disease, which comprises delivering a composition of the invention to the patient or animal. In addition, the composition of this invention may be useful to elicit a immune response in the patient or animal affected with CNS, which comprises delivering a composition of the invention to the patient or animal.
- Moreover, this invention provides polynucleotide variant fragments capable of hybridizing under stringent conditions with the natural tetanus toxin sequence. The stringent conditions are for example as follows: at 42° C. for 4 to 6 hours in the presence of 6×SSC buffer, 1× Denhardt's Solution, 1% SDS, and 250 μg/ml of tRNA. (1×SSC corresponds to 0.15 M NaCl and 0.05 M sodium citrate; 1× Denhardt's solution corresponds to 0.02% Ficoll, 0.02% polyvinyl pyrrolidone and 0.02% bovine serum albumin). The two wash steps are performed at room temperature in the presence of 0.1×SCC and 0.1% SDS.
- A polynucleotide variant fragment means a polynucleotide encoding for a tetanus toxin sequence derived from the native tetanus toxin sequence and having the same properties of transport.
- In addition, the invention provides a vector comprising a promoter capable of expression in muscle cells and optionally an enhancer, a nucleic acid sequence coding for the fragment of tetanus toxin of the invention or an amino acid variant fragment of the invention associated with a polynucleotide coding for a protein α a polypeptide of interest. In a preferred embodiment of the invention the promoter can be the CMV promoter and preferably the CMV promoter contained in pcDNA 3.1 (In Vitrogen, ref. V790-20), or the promoter β actin as described in Bronson S. V. et al. (PNAS, 1996, 93:9067-9072).
- In addition, the invention provides a vector comprising a promoter capable of expression in neuronal cells or in precursors (such NT2(hNT) precursor cells from Stratagene reference # 204101) and optionally an enhancer, a nucleic acid sequence coding for the fragment of tetanus toxin of the invention or an amino acid variant fragment of the invention associated with a polynucleotide coding for a protein or a polypeptide of interest. In a preferred embodiment of the invention the promoter can be β actin (see the above reference). These vectors are useful for the treatment of a patient or an animal infected with CNS disease comprising delivering the vector of the invention to the patient or animal. In addition, these vectors are useful for eliciting immune responses in the patient or animal.
- One advantage of the present invention comprising the fragment of tetanus toxin (fragment A, B, and C) is to obtain a better transport of the fragment inside the organism compared with fragment C. Another advantage of the composition of the invention is to obtain a well defined amino acid sequence and not a multimeric composition. Thus, one can easily manipulate this composition in gene therapy.
- In another embodiment, this invention provides a method of modulating the transport in a neuron of a neurotoxin, such as the tetanus toxin, or a fusion protein comprising a fragment C of the tetanus toxin. These methods comprise administering neurotrophic factors such as BDNF, NT-4, and GDNF, and agonists and antagonists thereof, to modulate internalization at a neuromuscular junction of a neurotoxin or a fusion protein comprising the TTC fragment according to the invention.
- In one embodiment, these methods further comprise administering to the neuron a TrkB receptor agonist or a TrkB receptor antagonist in an amount sufficient to modulate the neuronal transport of the tetanus toxin or the fusion protein. The term “modulate” and its cognates refer to the capability of a compound acting as either an agonist or an antagonist of a certain reaction or activity. The term modulate, therefore, encompasses the terms “increase” and “decrease.” The term “increase,” for example, refers to an increase in the neuronal transport of a polypeptide in the presence of a modulatory compound, relative to the transport of the polypeptide in the absence of the same compound. Analogously, the term “decrease” refers to a decrease in the the neuronal transport of a polypeptide in the presence of a modulatory compound, relative to the transport of the polypeptide in the absence of the same compound. The neuronal transport of polypeptides can be measured as decribed herein or by techniques generally known in the art.
- The TrkB receptor agonists include neurotrophic factors that activate a TrkB receptor, such as a Brain Derivated Neurotrophic Factor or a
Neurotrophin 4. The TrkB receptor agonists can also include antibodies that bind to TrkB receptors and activate them. These methods of using TrkB receptor agonists provide useful methods for enhancing the neuronal transport of a tetanus toxin or a tetanus toxin fusion protein. - The TrkB receptor antagonists include antibodies that bind to a TrkB receptor agonist, such as those described above, and thereby decrease the activation of a TrkB receptor. For example, these antibodies can be directed to neurotrophic factors that activate a TrkB receptor, such as a Brain Derivated Neurotrophic Factor or a
Neurotrophin 4. In addition, TrkB receptor antagonists include antibodies that bind to TrkB receptors and inactivate them. These methods of using TrkB receptor agonists provide useful methods for decreasing or preventing the neuronal transport of a tetanus toxin or a tetanus toxin fusion protein. - In another embodiment, these methods further comprise administering to the neuron a GFRα/cRET receptor agonist or a GFRα/cRET receptor antagonist in an amount sufficient to modulate the neuronal transport of the tetanus toxin or the fusion protein.
- The GFRα/cRET receptor agonists include neurotrophic factors that activate a GFRα/cRET receptor, such as a Glial-Derived Neurotrophic Factor. The GFRα/cRET receptor agonists can also include antibodies that bind to GFRα/cRET receptors and activate them. These methods of using GFRα/cRET receptor agonists provide useful methods for enhancing the neuronal transport of a tetanus toxin or a tetanus toxin fusion protein.
- The GFRα/cRET receptor antagonists include antibodies that bind to a GFRα/cRET receptor agonist, such as those described above, and thereby decrease the activation of a GFRα/cRET receptor. For example, these antibodies can be directed to neurotrophic factors that activate a GFRα/cRET receptor, such as a Glial-Derived Neurotrophic Factor. In addition, GFRα/cRET receptor antagonists include antibodies that bind to GFRα/cRET receptors and inactivate them. These methods of using GFRα/cRET receptor agonists provide useful methods for decreasing or preventing the neuronal transport of a tetanus toxin or a tetanus toxin fusion protein.
- In these methods, the agonist or antagonist can be administered to neuronal cells that already contain a tetanus toxin or a fusion protein. Alternatively, the tetanus toxin or fusion protein can be administered concurrently with or after the administration of the agonist or antagonist.
- In one embodiment, the TTC-containing fusion proteins of the present invention comprises a second protein that is encoded by a reporter gene, such as the lac Z gene or the Green Fluorescent Protein gene. Such fusion proteins are useful for visualizing modulation of the synaptic plasticity in vivo, including in a human, for example by magnetic resonance imaging. For example, the fusion proteins can be used to monitor and detect the effects of a compound, such as a neurotrophic factor, on neuronal transport. In these methods, the compound and the fusion protein are administered to a neuron, and the fusion protein is detected to determine the effect of the compound on the neuronal transport. In addition, the fusion proteins can be used to detect modifications in trafficking patterns within a restricted neural network, such as those used in known animal models for neurodegenerative diseases. The fusion proteins can also be used in screening methods to detect compounds that reduce or prevent neuronal transport of a tetanus toxin. Compounds so identified can be used to prevent or treat tetanus infections.
- The TTC fragment can also be coupled to a neurotrophic factor and administered to a patient to treat CNS pathologies associated with production defects of different factors. The TTC fragment could also be used as a vector for modulating interactions with proteins involved in neurodegenerative diseases.
- The present invention also provides compositions comprising a TrkB receptor agonist or a GFRα/cRET receptor agonist and a fusion protein comprising a fragment C of the tetanus toxin fused to a second protein. In one embodiment, the TrkB agonist is a neurotrophic factor such as a Brain Derivated Neurotrophic Factor or a
Neurotrophin 4. In another embodiment, the GFRα/cRET receptor agonist is a neurotrophic factor, such as Glial-Derived Neurotrophic Factor - This invention will be more fully described with reference to the drawings in which:
-
FIG. 1 shows the DNA sequence and amino acid sequence of the TTC fragment cloned in pBS:TTC. -
FIG. 2 shows the details of construct pBS:TTC, which is further described in Example 1. -
FIG. 3 depicts pGEX-lacZ-TTC construct. -
FIG. 4 shows construct pGEX:TTC-lacZ. -
FIG. 5 depicts the details of the construct pCMV:lacZ-TTC. -
FIG. 6 shows the confocal immunofluorescence analysis of GFP-TTC membrane traffic at mature mouse LAL NMJs. - (A) Two hours after the subcutanous injection of GFP-TTC in the vicinity of the LAL muscle, the probe (green) was concentrated at motor nerve endings of NMJ. Associated intramuscular motor axons were immunostained (red) with an antibody against NF200. GFP-TTC labeling was also detected in sensory nerve fibers (arrows) and at the nodes of Ranvier of myelinated axons (arrowheads). (B) Strong nodal labeling With GFP-TTC (green) (arrow) in a single living myelinated axon. Myelin was passively stained with RH414 dye (red). (C) Two hours after injection as in A, LAL muscle fibers were fixed and labeled for troponin T by indirect immunofluorescence. (C′ and C″) Inset is a side view image of a NMJ showing that GFP-TTC staining (green) is located presynaptically. (D-G) LAL was harvested at various times after GFP-TTC injection and NMJ identified in red by labeling with TRITC-a-BTX (D′-G′). D-D′: 5 min; E-E′ 30 min; F-F′: 2 h and G-G′:24 h.
- Scale bars: A, 20 μm; B, 8 μm; C: 20 μm; D, 2 μm; E-G, 5 μm.
-
FIG. 7 shows that BDNF increases GFP-TTC recruitment at the NMJ in a dose-dependent manner. - (A1-A6) The NMJ on LAL muscles was identified by TRIT-
a-BTX labeling 30 min after in vivo co-injection of GFP-TTC with various amounts of BDNF. The level of GFP fluorescence was quantified over these areas (see B). An enhancement of axonal labeling (arrows), more prononced with higher BDNF concentration, was also detected. Scale bars: 20 μm (B) Confocal sections of the NMJ were collected for analysis and projections generated. TRIT-a-BTX labeling determines the area of the NMJ over which the global GFP fluorescent signal was measured. For each, (n=15-20), the GFP fluorescence was divided by NMJ area (in μm2) to obtain the fluorescence level. Error bars indicate S.D. ** P<0.005; t-test, vs control. -
FIG. 8 depicts the immunofluorescence visualization of TrkB at the LAL NMJ. Two hours after GFP-TTC injection in LAL, confocal analysis was performed. (A-B) The fusion protein was identified in green directly by GFP fluorescence. (C-D) TrkB, identified (in red) by indirect immunofluorescence (see material and methods), was located at the NMJ. (E-F) However, when the two projections were overlaid, no overlap was found between the TrkB and the GFP-TTC signals. - Scale bar: Top: 5 μm; Bottom: 2 μm
-
FIG. 9 represents the results of experiments elucidating the mechanisms of GFP-TTC recruitment to the NMJ. - (A) Quantification of GFP-TTC fluorescence was performed, as described in
FIG. 7 at various time after co-injection with or without 50 ng BDNF. - (B) After in vitro loading for 45 min with GFP-TTC, the excised LAL muscle was fixed and SV2 protein detected by indirect immunofluorescence (red). SV2 labeling was mostly diffuse and concentrated in a few areas of the NMJ (arrows). Colocalization of SV2 with GFP-TTC staining was only observed in a very limited number of areas. Scale bar: 8 μm.
- (C) Treatment with botulinum type-A neurotoxin to block synaptic vesicles exocytosis and endocytosis. 48 hours after BoTx/A injection (as described in material and methods), GFP-TTC, associated or not with 50 ng BDNF, was injected in LAL muscle and GFP fluorescence quantified as previously. ** P<0.005; t-test, vs control; * P<0.005; t-test vs BOTx/A treatment.
- (D) Comparison of KCl induced depolarization and BDNF effects on GFP-TTC localization at the NMJ.
-
FIG. 10 depicts the localization of GFP-TTC probe in lipid microdomains. - (A) 2 hours after intramuscular injection, GFP-TTC was found in detergent resistant membranes (DRMs) (lanes 4-6) isolated from gastroenemius muscle, which also contained the raft marker caveolin-3. A small amount of GFP-TTC was also detected in the soluble fraction (lane 12).
- (B) GFP-TTC colocalized with the raft marker GM1 at the NMJ. NMJ were identified by Alexa 647-a-BTX binding (in blue). Whereas GFP-TTC was detected in less than 5 min at the NMJ, CT-b requires 3-5 hours. At this time, a diffuse staining which colocalized with the similar GFP-TTC labeling, was obtained, while a few patches labeling only for CT-b were also observed.
- (C) Intensity profiles of GFP-TTC (green) and Alexa 594 labeled-CT-b (red) were performed 5 or 24 h after intramuscular co-injection of both probes in gastrocnemius.
- Scale bar: 5 μm.
-
FIG. 11 shows a comparison of GFP-TTC and CT-b localization in motoneuron cell bodies. Twenty four hours after βgal-TTC (A) or GFP-TTC and CT-b (B-E) intramuscular injection in gastrocnemius muscle, mice were perfused intracardially and their spinal cords removed. (A) X-gal reaction on spinal cord transerve sections showed labeling in motoneuron cell bodies but also in neurites (inset). (B) GFP-TTC and CT-b were detected on longitudinal section of spinal cord in a significant number of motoneurons. (C) Probes were detected in vesicles highly concentrated in cell bodies but also in neurites. (D) In neuronal extensions, GFP-TTC and CT-b were detected in different vesicular-like structures. Note that only few of them were positive for both probes. (E) Note that neither GFP-TTC nor CT-b were detected in the nucleus as shown in one optical section. - Scale bars: A, 0.2 mm; inset, 50 μm; B, 20 μm; C, 10 μm; D, 5 μm; E, 2 μm.
- Tetanus toxin is a potent neurotoxin of 1315 amino acids that is produced by Clostridium tetani (1, 2). It prevents the inhibitory neurotransmitter release from spinal cord interneurons by a specific mechanism of cell intoxication (for review see ref 3). This pathological mechanism has been demonstrated to involve retrograde axonal and transynaptic transport of the tetanus toxin. The toxin is taken up by nerve endings at the neuromuscular junction, but does not act at this site; rather, the toxin is transported into a vesicular compartment and travels along motor axons for a considerable distance until it reaches its targets. The transynaptic movement of tetanus toxin was first demonstrated by autoradiographic localization in spinal cord interneurons after injection into a muscle (4). However, previous studies of transynaptic passage of tetanus toxin from motoneurons were limited by the rapid development of clinical tetanus and death of the experimental animal (4, 5, 6).
- A fragment of tetanus toxin obtained by protease digestion, the C fragment, has been shown to be transported by neurons in a similar manner to that of the native toxin without causing clinical symptoms (7, 8, 9, 10). A recombinant C fragment was reported to possess the same properties as the fragment obtained by protease digestion (11). The fact that an atoxic fragment of the toxin molecule was able to migrate retrogradely within the axons and to accumulate into the CNS led to speculation that such a fragment could be used as a neurotrophic carrier (12). A C fragment chemically conjugated to various large proteins was taken up by neurons in tissue culture (13) and by motor neurons in animal models (ref. 12, 14, and 15). According to the invention the fragment of tetanus toxin consists of a non-toxic proteolytic fragment of tetanus toxin (TT) comprising a fragment C and a fragment B or a fraction thereof of at least 11 amino acid residues or a non-toxic proteolytic fragment of tetanus toxin (TT) comprising a fragment C and a fragment B or a fraction thereof of at least 11 amino acids residues and a fraction of a fragment A devoid of its toxic activity corresponding to the proteolytic domain having a zinc-binding motif located in the central part of the chain between the amino acids 225 and 245 (cf. Montecucco C. and Schiavo G. Q. Rev. Biophys., (1995), 28:423-472). Thus the fraction of the fragment A comprises, for example, the
amino acid sequence 1 to 225 or the amino acid sequence 245 to 457, or theamino acid sequence 1 to 225 associated with amino acid sequence 245 to 457. - The molecule having a biological function is selected from the group consisting of protein of interest, for example, for the compensation or the modulation of the functions under the control of the CNS or the spinal cord or the modulation of the functions in the CNS or the spinal cord, or protein of interest to be delivered by gene therapy expression system to the CNS or the spinal cord. The proteins of interest are, for example, the protein SMN implicated in spinal muscular atrophy (Lefebvre et al., Cell, (1995), 80:155-165 and Roy et al., Cell, (1955), 80:167-178); neurotrophic factors, such as BDNF (Brain-derived neurotrophic factor); NT-3 (Neurotrophin-3); NT-4/5; GDNF (Glial cell-line-derived neurotrophic factor); IGF (Insulin-like growth factor) (Oppenheim, Neuron, (1996), 17:195-197; Thoenen et al., Exp. Neurol., (1933), 124:47-55 and Henderson et al., Adv. Neurol., (1995), 68:235-240); or PNI (protease nexin 1) promoting neurite outgrowth (this factor can be used for the treatment of Alzheimer disease (Houenou et al., PNAS, (1995), 92:895-899)); or SPI3 a serine protease inhibitor protein (Safaei, Dev. Brain Res., (1997), 100: 5-12); or ICE (Interleukin-1β converting Enzyme) a factor implicated in apoptosis, to avoid apoptosis (Nagata, Cell, (1997), 88:355-365); or Bcl-2, a key intracellular regulator of programmed cell death (Jacobson, M. D. (1997), Current Biology, 7:R277-R281); or green fluorescent protein (Lang et al., Neuron, (1997), 18:857-863) as a marker; enzyme (ex: β-Gal); endonuclease like 1-Scel (Choulika A., et al. (1995), Molecular and Cellular biology, 15 (4):1968-1973 or CRE (Gu H., et al. (1994), Science, 265:103-106); specific antibodies; drugs specifically directed against neurodegenerative diseases such as latero spinal amyotrophy. Several molecules can be associated with a TT fragment.
- In association means an association obtained by genetic recombination. This association can be realized upstream as well as downstream to the TT fragment The preferred mode of realization of the invention is upstream and is described in detail; a downstream realization is also contemplated. (Despite Halpern et al., J. Biol. Chem., (1993), 268(15):11188-11192, who indicated that the carboxyl-terminal amino acids contain the domain required for binding to purified gangliosides and neuronal cells.)
- The desired CNS area means, for example, the tongue which is chosen to direct the transport to hypoglossal motoneuron; the arm muscle which is chosen to direct the transport to the spinal cord motoneurons.
- For this realization of transplantation of a neuron to the CNS or the spinal cord see Gage, F. H. et al. (1987), Neuroscience, 23:725-807, “Grafting genetically modified cells to the brain: possibilities for the future.”
- The techniques for introducing the polynucleotides to cells are described in U.S. Pat. Nos. 5,580,859 and 5,589,466, which is relied upon and incorporated by reference herein. For example, the nucleotides may be introduced by transfection in vitro before reimplantation in area of the CNS or the spinal cord.
- A chemical linkage is considered for a particular embodiment of the invention and comprises the association between the TT fragment and a polynucleotide encoding the molecule of interest with its regulatory elements, such as promoter and enhancer capable of expressing said polynucleotide. Then the TT fragment allows the retrograde axonal transport and/or the transynaptic transport, and the product of the polynucleotide is expressed directly in the neurons. This chemical linkage can be covalent or not, but preferably covalent performed by thiolation reaction or by any other binding reaction as described in “Bioconjugate Techniques” from Gret T. Hermanson (Academic press, 1996).
- The axonal retrograde transport begins at the muscle level, where the composition of interest is taken up at the neuromuscular junction, and migrates to the neuronal body of the motoneurons (which are also called the first order neurons) in the CNS or spinal cord. First order neurons mean neurons that have internalized the composition of interest, and thus in this case, correspond to motoneurons.
- The transynaptic retrograde transport corresponds to interneuron communications via the synapses from the motoneurons, and comprises second order neurons and higher order neurons (fourth order corresponding to neurons in the cerebral cortex).
- The different stages of the neuronal transport are through the neuromuscular junction, the motoneuron, also called first order neuron, the synapse at any stage between the neurons of different order, neuron of order second to fourth order, which corresponds to the cerebral cortex.
- In one embodiment of this invention, it is shown that a β-gal-TTC (TT-fragment C) hybrid protein retains the biological activities of both proteins in vivo. Therefore, the hybrid protein can undergo retrograde and transneuronal transport through a chain of interconnected neurons, as traced by its enzymatic activity. These results are consistent with those of others who used chemically conjugated TTC, or TTC fused to other proteins (12, 13, 14, 15). In these in vitro analyses, the activity of the conjugated or hybrid proteins was likewise retained or only weakly diminished. Depending on the nature of the TTC fusion partner, different types of potential applications can be envisioned. For example, this application can be used to deliver a biologically active protein into the CNS for therapeutic purposes. Such hybrid genes can also be used to analyze and map synaptically connected neurons if reporters; such as lacZ or the green fluorescent protein (GFP; 29) gene, were fused to TTC.
- The retrograde transport of the hybrid protein may be demonstrated as follows. When injected into a muscle, β-gal activity rapidly localized to the somata of motoneurons that innervate the muscle. The arborization of the whole nerve, axon, somata and dendrites can easily be visualized. However, in comparison to the neurotropic viruses, the extent of retrograde transneuronal transport of the hybrid protein from the hypoglossal neurons indicates that only a subset of interconnected neurons is detected, although most areas containing second-order interneurons have been identified by the β-gal-TTC marker. Transneuronal uptake is mostly restricted to second order neurons. In such experiments, when a limited amount of a neuronal tracer is injected into a muscle or cell, only a fraction will be transported through a synapse, thereby imposing an experimental constraint on its detection. Presently, the most efficient method, in terms of the extent of transport, relies on neurotropic viruses. Examples include: alpha-herpes viruses, such as herpes simplex type 1 (HSV-1), pseudorabies virus (PrV), and rhabdoviruses (24, 25). Viral methods are very sensitive because each time a virus infects a new cell, it replicates, thereby amplifying the signal and permitting visualization of higher order neurons in a chain. Ultimately, however, one wants to map a neuronal network in an in vivo situation such as a transgenic animal. Here, the disadvantage of viral labeling is its potential toxicity. Most viruses are not innocuous for the neural cell, and their replication induces a cellular response and sometimes cell degeneration (24). Furthermore, depending on experimental conditions, budding of the virus can occur leading to its spread into adjoining cells and tissues.
- Differences in mechanisms of transneuronal migration could also account for the restricted number of neurons labeled by β-gal-TTC. Matteoli et al have provided strong evidence that the intact tetanus toxin crosses the synapses by parasitizing the physiological process of synaptic vesicle recycling at the nerve terminal (22). The toxin probably binds to the inner surface of a synaptic vesicle during the time the lumen is exposed to the external medium. Vesicle endocytosis would then presumably provide the mechanism for internalization of the toxin. Because the TTC fragment is known to mimic the migration of the toxin in vivo, it could therefore direct the fusion protein along a similar transynaptic pathway. If this hypothesis is confirmed, it would strongly suggest that synaptic activity is required for the transneuronal transport of β-gal-TTC. Therefore, only active neuronal circuits would be detected by the hybrid protein. The possible dependence of β-gal-TTC on synaptic vesicle exocytosis and endocytosis could be further investigated, since techniques are now available to record synaptic activity in neural networks in vitro (30). In contrast, the transneuronal pathway of neurotropic viruses has not yet been elucidated and could be fundamentally different, involving virus budding in the vicinity of a synapse. Finally, the transneuronal transport of the hybrid protein might depend on a synaptic specificity, although the tetanus toxin is not known to display any (7, 23). It is therefore likely that a virus would cross different or inactive synapses. In summary, the restricted spectrum of interneuronal transport, in addition to its non-toxicity, make the β-gal-TTC hybrid protein a novel and powerful tool for analysis of neural pathways.
- One advantage of the fusion gene of the invention for neuronal mapping is that it derives from a single genetic entity that is amenable to genetic manipulation and engineering. Several years ago, a technique based on homologous recombination in embryonic stem cells was developed to specifically replace genes in the mouse (31, 32). This method generates a null mutation in the substituted gene, although in a slightly modified strategy, a dicistronic messenger RNA can also be produced (33, 34). When a reporter gene, such as E. coli lacZ, is used as the substituting gene, this technique provides a means of marking the mutated cells so that they can be followed during embryogenesis. Thus, this technique greatly simplifies the analysis of both the heterozygote expression of the targeted gene as well as the phenotype of null (homozygous) mutant animals.
- Another advantage of this invention is that the composition comprising the fusion gene may encode an antigen or antigens. Thus, the composition may be used to elicit an immune response in its host and subsequently confer protection of the host against the antigen or antigens expressed. These immunization methods are described in Robinson et al., U.S. Pat. No. 5,43,578, which is herein incorporated by reference. In particular, the method of immunizing a patient or animal host comprises introducing a DNA transcription unit encoding comprising the fusion gene of this invention, which encodes a desired antigen or antigens. The uptake of the DNA transcription unit by the host results in the expression of the desired antigen or antigens and the subsequent elicitation of humoral and/or cell-mediated immune responses.
- Neural cells establish specific and complex networks of interconnected cells. If a gene were mutated in a given neural cell, we would expect this mutation to have an impact on the functions of other, interconnected neural cells. With these considerations in mind, a genetic marker that can diffuse through active synapses would be very useful in analyzing the effect of the mutation. In heterozygous mutant animals, the cells in which the targeted gene is normally transcribed could be identified, as could the synaptically connected cells of a neural network. In a homozygous animal, the impact of the mutation on the establishment or activity of the neural network could be determined. The feasibility of such an in vivo approach depends critically on the efficiency of synaptic transfer of the fusion protein, as well as its stability and cellular localization.
- Another extension of the invention is to gene therapy applied to the CNS. This invention provides for uptake of a non-toxic, enzyme-vector conjugate by axon terminals and conveyance retrogradely to brainstem motoneurons. A selective retrograde transynaptic mechanism subsequently transports the hybrid protein into second-order connected neurons. Such a pathway, which by-passes the blood-brain barrier, can deliver macromolecules to the CNS. In fact, pathogenic agents, such as tetanus toxin and neurotropic viruses, are similarly taken up by nerve endings, internalized, and retrogradely transported to the nerve cell somata. In such a scenario, the lacZ reporter would be replaced by a gene encoding a protein that provides a necessary or interesting activity and/or function. For example, the human CuZn superoxide dismutase, SOD-1, and the human enzyme β-N-acetylhexosaminidase A, HexA, have been fused or chemically coupled to the TTC fragment (13, 16), and their uptake by neurons in vitro was considerably increased and their enzymatic functions partially conserved. Combined with the in vivo experiments described here using β-gal-TTC, a gene therapy approach based on TTC hybrid proteins appears to be a feasible method of delivering a biological function to the CNS. However, ways have to be found to target the TTC hybrid proteins, which are likely to be sequestrated into vesicles, to the appropriate subcellular compartment. Such a therapeutic strategy could be particularly useful for treating neurodegenerative and motoneuron diseases, such as amyotrophy lateral sclerosis (ALS, 35), spinal muscular atrophies (SMA, 36, 37), or neurodegenerative lysosomal storage diseases (38, 39). Injection into selected muscles, even in utero, could help to specifically target the appropriate neurons. In addition, such an approach would avoid the secondary and potentially toxic effects associated with the use of defective viruses to deliver a gene (40, 41).
- (A) TTC Cloning:
- Full length TTC DNA was generated from the genomic DNA from the Clostridium Tetani strain (a gift from Dr. M. Popoff, Institut Pasteur) using PCR. Three overlapping fragments were synthesized: PCR1 of 465 bp (primer 1: 5′-CCC CCC GGG CCA CCA TGG TTT TTT CAA CAC CM TTC CAT TTT CTT ATT C-3′ (SEQ ID NO:4) and primer 2: 5′-CTA MC CAG TM TTT CTG-3′ (SEQ ID NO:5)), PCR2 of 648 bp (primer 3: 5′-MT TAT GGA CTT TM MG ATT CCG C-3′ (SEQ ID NO:6) and primer 4: 5′-GGC ATT ATA ACC TAC TCT TAG MT-3′ (SEQ ID NO:7)) and PCR3 of 338 bp (primer 5: 5′-AAT GCC TTT MT MT CTT GAT AGA MT-3′ (SEQ ID NO:8) and primer 6: 5′-CCC CCC GGG CAT ATG TCA TGA ACA TAT CM TCT GTT TAA TC-3′ (SEQ ID NO:9)). The three fragments were sequentially introduced into pBluescript KS+ (Stratagene) to give pBS:TTC plasmid. The
upstream primer 1 also contains an optimized eukaryotic Ribosome Binding Site (RBS) and translational initiation signals. Our TTC fragment (462 amino acids) represents the amino acids 854-1315 of tetanus holotoxin, i.e. the carboxy-terminal 451 amino acids of the heavy chain, which constitute the fragment C plus 11 amino acids of the heavy chain that immediately precede the amino terminus of the fragment C. The DNA sequence and amino acid sequence of the TTC fragment cloned in pBS:TTC is shown inFIG. 1 . The construct pBS:TTC is shown inFIG. 2 . - (B) pGEX:lacZ-TTC:
- pGEX:lacZ was obtained by cloning a SmaI/XhoI lacZ fragment from the pGNA vector (a gift from Dr. H. Le Mouellic) into
pGEX 4T-2 (Pharmacia). PCR was used to convert the lacZ stop codon into an NcoI restriction site. Two primers (upstream: 5′-CTG MT ATC GAC GGT TTC CAT ATG-3′ (SEQ ID NO:10) and downstream: 5′-GGC AGT CTC GAG TCT AGA CCA TGG CTT TTT GAC ACC AGA C-3′ (SEQ ID NO:11)) were used to amplify the sequence between NdeI and XhoI, generating pGEX:lacZ(NcoI) from pGEX:lacZ. pGEX:lacZ-TTC was obtained by insertion of the TTC NcoI/XhoI fragment into pGEX:lacZ(NcoI), fusing TTC immediately downstream of the lacZ coding region and in the same reading frame.FIG. 3 shows the details of the pGEX:lacZ-TTC construct. - (C) pGEX:TTC-lacZ:
- pBS:TTC was modified to change NcoI into a BamHI restriction site (
linker 5′-CAT GAC TGG GGA TCC CCA GT-3′ (SEQ ID NO:12)) at the start of the TTC DNA, to give pBS:TTC(BamHI) plasmid. pGEX:TTC was obtained by cloning The TTC BamHI/SmaI fragment from pBS:TTC(BamHI) intopGEX 4T-2 (Pharmacia) PCR was used to convert the TTC stop codon into an NheI restriction site. Two primers (upstream: 5′-TAT GAT AAA AAT GCA TCT TrA GGA-3′ (SEQ ID NO:13) and downstream: 5′-TGG AGT CGA CGC TAG CAG GAT CAT TTG TCC ATC CTT C-3′ (SEQ ID NO:14)) were used to amplify the sequence between NsiI and SmaI, generating pGEX:TTC(NheI) from pGEX:TTC. The lacZ cDNA from plasmid pGNA was modified in its 5′ extremity to change SacII into an NheI restriction site (linker 5′-GCT AGC GC-3′ (SEQ ID NO:15)). pGEX:TTC-lacZ was obtained by insertion of the lacZ NheI/XhoI fragment into pGEX:TTC(NheI), fusing lacZ immediately downstream of the TTC coding region and in the same reading frame. The details of the construct of pGEX:TTC-lacZ are shown inFIG. 4 . - (D) pCMV:lacZ-TTC:
- pCMV vector was obtained from pGFP-C1 (Clontech laboratories) after some modifications: GFP sequence was deleted by a BgIII/NheI digestion and relegation, and SacII in the polylinker was converted into an AscI restriction site (
linkers 5′-GATATC GGC GCG CCA GC-3′ (SEQ ID NO:16) and 5′-TGG CGC GCC GAT ATC GC-3′ (SEQ ID NO:17)). - pBluescript KS+ (Stratagene) was modified to change XhoI into an AscI restriction site (
linker 5′-TCG ATG GCG CGC CA-3′ (SEQ ID NO:18)), giving pBS(AscI) plasmid. pBS:lacZ-TTC was obtained by cloning a XmaI lacZ-TTC fragment from pGEX:lacZ-TTC into pBS(AscI). pCMV:lacZ-TTC was obtained by insertion of the lacZ-TTC XmnI/AscI fragment into pCMV vector at the XhoI and AscI sites (XhoI and XmnI was eliminated with the clonage), putting the fusion downstream of the CMV promotor.FIG. 8 shows the details of the construct pCMV:lacZ-TTC. Plasmid pCMV:lacZ-TTC was deposited on Aug. 12, 1997, at the Collection Nationale de Cultures de Microorganisms (CNCM), institut Pasteur, 25, Rue de Docteur Roux, F-75724,Paris Cedex 15, France, under Accession No. 1-1912. - The E. coli strain SR3315 (a gift from Dr. A. Pugsley, Institut Pasteur) transfected with pGEX:lacz-TTC was used for protein production. An overnight bacterial culture was diluted 1:100 in LB medium containing 100 μg/ml ampicillin, and grown for several hours at 32° C. until an OD of 0.5 was reached. Induction from the Ptac promoter was achieved by the addition of 1 mM IPTG and 1 mM MgCl2 and a further 2 hrs incubation. The induced bacteria were pelleted by centrifugation for 20 min at 3000 rpm, washed with PBS and resuspended in lysis buffer containing 0.1M Tris pH 7.8, 0.1M NaCl, 20% glycerol, 10 mM EDTA, 0.1% Triton-X100, 4 mM DTT, 1 mg/ml lysosyme, and a mixture of anti-proteases (100 μg/ml Pefablok, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 1 mM benzamidine). After cell disruption in a French Press, total bacterial lysate was centrifuged for 10 min at 30000 rpm. The resulting supernatant was incubated overnight at 4° C. with the affinity matrix Glutathione Sepharose 4B (Stratagene) with slow agitation. After centrifugation for 5 min at 3000 rpm, the matrix was washed three times with the same lysis buffer but without lysosyme and glycerol, and then three times with PBS. The resin was incubated overnight at 4° C. with Thrombin (10 U/ml; Sigma) in PBS in order to cleave the β-gal-TTC fusion protein from the Glutatione-S-transferase (GST) sequence and thereby elute it from the affinity column. Concentration of the eluted fusion protein was achieved by centrifugation in centricon X-100 tubes (Amicon; 100,000MW cutoff membrane).
- Purified hybrid protein was analyzed by Western blotting after electrophoretic separation in 8% acrylamide SDS/PAGE under reducing conditions followed by electrophoretic transfer onto nitrocellulose membranes (0.2 mm porosity, BioRad). Immunodetection of blotted proteins was performed with a Vectastaln ABC-alkaline phosphatase kit (Vector Laboratories) and DAB color development. Antibodies were used as follows: rabbit anti-β-gal antisera (Capel), dilution 1:1000; rabbit anti-TTC antisera (Calbiochem), dilution 1:20000. A major band with a relative molecular mass of 180 kDa corresponding to the β-Gal-TTC hybrid protein was detected with both anti-β-Gal anti-TTC antibodies.
- The 1009 cell line was derived from a spontaneous testicular teratocarcinoma arising in a recombinant inbred mouse strain (129×B6) (17). The 1009 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum and passaged at subconfluence. In vitro differentiation with retinoic acid and cAMP was performed as described (18). Eight days after retinoic acid treatment, cells were used for the internalization experiments with either the hybrid protein or β-gal.
- Binding and internalization of the β-Gal-TTC fusion were assessed using a modified protocol (16). Differentiated 1009 cells were incubated for 2 hrs at 37° C. with 5 μg/ml of β-Gal-TTC or β-Gal protein diluted in binding buffer (0.25% sucrose, 20
mM Tris acetate 1 mM CaCl2, 1 mM MgCl2, 0.25% bovine serum albumin, in PBS). The cells were then incubated with 1 μg/ml Pronase E (Sigma) in PBS for 10 min at 37° C., followed by washing with proteases inhibitors diluted in PBS (100 μg/ml Pefablok, 1 mM benzamidine). - The cells were fixed with 4% formalin in PBS for 10 min at room temperature (RT) and then washed extensively with PBS. β-gal activity was detected on fixed cells by an overnight staining at 37° C. in X-Gal solution (0.8 mg/ml X-Gal, 4 mM potassium ferricyanide, 4 mM potassium ferrocyanide, 4 mM MgCl2 in PBS). For electron microscopy, the cells were further fixed in 2.5% glutaraldehyde for 18 hrs, and then-processed as described (19).
- For immunohistochemical labeling, cells were fixed with 4% paraformaldehyde in PBS for 10 min at RT then washed extensively with PBS, followed by a 1 hr incubation at RT with 2% BSA/0.02% Triton X-100 in PBS. Cells were co incubated in primary antibodies diluted in 2% BSA/0.02% Triton X-100 in PBS for 2 hrs at RT. Antibodies used were a mouse anti-neurofilament antibody (
NF 200 Kd, dilution 1:50; Sigma) or the rabbit anti-TTC antibody (dilution 1:1000). The labeling was visualized using fluorescent secondary antibodies: Cy3, goat anti-rabbit IgG (dilution 1:500; Amersham) or anti-mouse IgG with extravidin-FITC (dilution 1:200; Sigma). Cells were mounted in moviol and visualized with epifluorescence. - 14-week old B6D2 μl mice were obtained from IFFA-CREDO. The animal's tongue muscle was injected using an Hamilton syringe (20 μl per animal) while under general anesthesia with 3% Avertin (15 μl/g of animal). The protein concentration was 0.5 to 5 μg/μl in PBS; therefore, mice received approximately 10 to 100 μg per injection. Animals were kept alive for 12 hrs to 48 hrs post-injection to permit migration of the injected protein, and in no case were any tetanus symptoms detected. The mice were sacrificed by intracardiac perfusion with 4% paraformaldehyde in PBS while under deep anesthesia. Brains were harvested, rinsed in PBS and incubated in 15% sucrose overnight at 4° C., then mounted in tissue-tek before sectioning, 15 μm thick slices using a cryostat.
- For in toto X-Gal staining of the dissected brain and tongue, mice (10 animals) were sacrificed and fixed as described above. The brain was further cut with a scalpel along a median plane and directly incubated for 12 hrs in X-Gal solution.
- For immunohistology, sections were incubated In a 1:5000 dilution of anti-TTC antibody in 2% BSA/0.02% Triton X-100 in PBS overnight at 4° C. after nonspecific antibody binding sites were blocked by a 1 hr incubation in the same buffer. Antibody detection was carried out using the Vectastain ABC-alkaline phosphatase kit with DAB color development. For X-Gal staining, sections were incubated in X-Gal solution and counterstained for 30 sec with hematoxylin 115 (v/v) in PBS. Histology on adjacent sections was done after X-Gal staining, using a 30 sec incubation in hematoxylin/thionin solution. All sections were mounted in moviol before eight microscopy analysis.
- Differentiation of 1009 cells with retinoic acid and CAMP in vitro yields neuronal and glial cells (18, 20). X-Gal staining or immunolabeling were performed after incubation with the β-gal-TTC fusion protein or with either the β-gal or TTC proteins alone. Only when the hybrid protein was incubated with differentiated 1009 cells was a strong X-Gal staining detected in cells having a neuronal phenotype. No signal was detected when β-gal alone was incubated under the same conditions. A similar X-Gal staining pattern was obtained after pronase treatment of the cells to remove surface bound proteins, indicating that the hybrid protein had been internalized. The intracellular localization of the hybrid protein was further confirmed by electron microscopic analysis of X-Gal-stained cells. Furthermore, the enzymatic activity observed in axons seemed to be localized in vesicles associated with filaments, which is in agreement with previous work on TTC fragment or native tetanus toxin (14, 21, 22). Co-labeling with anti-TTC and anti-neurofilament antibodies revealed that β-gal activity co-localized with TTC fragment in neuronal cells. No glial cells were labeled with either antibody.
- The method used for the internalization was identical to that described in Example 6 above. The results show efficiently internalization of the hybrid as in Example 6 above.
- To study the behavior of the β-gal-TTC protein in vivo, the hybrid protein was tested in a well characterized neuronal network, the hypoglossal system. After intramuscular injection of β-gal-TTC protein into the mouse tongue, the distribution of the hybrid protein in the CNS was analyzed by X-Gal staining. Various dilutions of the protein were injected and sequential time points were analyzed to permit protein transport into hypoglossal motoneurons (XII), and its further transneuronal migration into connected second order neurons.
- A well-defined profile of large, apparently retrogradely labeled neurons was clearly evident in the hypoglossal structure, analyzed in toto at 12 hrs post-injection. A strong labeling was also apparent in the hypoglossal nerve (XIIn) of the tongue of the injected mice. At the level of muscle fibers, button structures were observed that might reflect labeling of neuromuscular junctions where the hybrid protein was internalized into nerve axons. These data demonstrate that the β-gal-TTC hybrid protein can migrate rapidly by retrograde axonal transport as far as motoneuron cell bodies, after prior uptake by nerve terminals in the tongue. This specific uptake and the intraaxonal transport are similar to the properties that have been described for the native toxin (6, 21, 23).
- Transport of the hybrid protein was examined in greater detail by analyzing X-Gal-stained brain sections. Motoneurons of the hypoglossal nucleus became labeled rapidly, with 12 hrs being the earliest time point examined. Most of the label was confined to neuronal somata, the cell nuclei being unlabeled. The intensity of the labeling depends upon the concentration of the β-gal-TTC protein injected: when 10 μg of protein was injected, only the hypoglossal somata were detected, whereas with 25 to 50 μg a fuzzy network of dendrites was visualized; transynaptic transfer was detected with 100 μg of hybrid protein. An identical distribution of label was observed then brain sections were immunostained with an anti-TTC antibody, demonstrating that β-gal and TTC fragment co-localize within cells. Finally, injection of β-gal alone did not result in labeling of the hypoglossal nuclei and therefore confirms that transport of the hybrid protein is TTC-dependent. Labeling with an anti-TTC antibody was less informative than detection of β-gal activity; for instance, the nerve pathway to the brain could not be visualized by anti-TTC immunostaining. At 18 hrs post-injection, labeling was observed in the hypoglossal nuclei: all motoneuron cell bodies and the most proximal part of their dendrites were very densely stained. In contrast, no labeling was ever detected in glial cells adjoining XII motoneurons or their axons. Our results are in accordance with others who reported an identical pattern of immunolabeling after injection of the TTC fragment alone (9). Transneuronal transfer is detectable after 24 hrs. An additional 24 hrs and beyond did not yield a different staining.
- Second order interneurons, as well as higher order neurons that synapse with the hypoglossal motoneurons, have been extensively analyzed using conventional markers, such as the wheat germ agglutinin-horseradish peroxidase complex (WGA-HRP) or neurotropic viruses such as alpha-herpes (24) and rhabdoviruses (25). An exhaustive compilation of regions in the brain that synaptically connect to the hypoglossal nucleus has also been described recently (25). In this invention, the distribution of the β-gal-TTC fusion depended on the initial concentration of protein injected into the muscle and the time allowed for transport after injection. Up to 24 hrs post-injection, labeling was restricted to the hypoglossal nuclei. After 24 hrs, the distribution of second order transneuronally labeled cells in various regions of the brain was consistent and reproducible. Even at longer time points (e.g. 48 hrs), labeling of the hypoglossal nucleus remained constant. At higher magnification, a discrete and localized staining of second-order neurons was observed, suggesting that the hybrid protein had been targeted to vesicles within cell somata, synapses and axons. A similar patchy distribution was previously described for tetanus toxin and TTC fragment alone (14, 21,22).
- Intense transneuronal labeling was detected in the lateral reticular formation (LRF), where medullary reticular neurons have been reported to form numerous projections onto the hypoglossal nucleus (26, 27). β-gal activity was detected bilaterally in these sections. Label led LRF projections formed a continuous column along the rostrocaudal axis, beginning lateral to the hypoglossal nucleus, with a few neurons being preferentially stained in the medullary reticular dorsal (MdD) and the medullary reticular ventral (MdV) nuclei. This column extends rostrally through the medulla, with neurons more intensely labeled in the parvicellular reticular nucleus (PCRt, caudal and rostral). After 48 hrs, cells in MdD and PCRt were more intensely stained. A second bilateral distribution of medullary neurons projecting to the hypoglossal nucleus was detected in the solitary nucleus (Sol) but the labeling was less intense than in the reticular formation, presumably because relatively few cells of the solitary nucleus project onto the hypoglossal nucleus (26). However, no labeling was found in the spinal trigeminal nucleus (Sp5), which has also been shown to project onto the hypoglossal nucleus (26). Transynaptic transport of the β-gal-TTC protein was also detected in the pontine reticular nucleus caudal (PnC), the locus coeruleus (LC), the medial vestibular nucleus (MVe) and in a few cells of the inferior vestibular nucleus (IV). These cell groups are known to project onto the hypoglossal nucleus (25), but their labeling was weak, probably because of the greater length of their axons. A few labeled cells were observed in the dorsal paragigantocellular nucleus. (DPGi), the magnocellular nucleus caudal (RMc), and the caudal raphe nucleus (R); their connections to the hypoglossal nucleus have also been reported (25). Finally, labeled neurons were detected bilaterally in midbrain projections, such as those of the mesencephalic trigeminal nucleus (Me5), and a few neurons were stained in the mesencephalic central gray region (CG). These latter nuclei have been typed as putative third order cell groups related to the hypoglossal nucleus (25).
- Neurons in the motor trigeminal nucleus (Mo5) and the accessory trigeminal tract (Acs5) were also labeled, along with a population of neurons in the facial nucleus (N7). However, interpretation of this labeling is more ambiguous, since it is known that motoneurons in these nuclei also innervate other parts of the muscular tissue, and diffusion of the hybrid protein might have occurred at the point of injection. Conversely, these nuclei may have also projected to the tongue musculature via nerve XII, since neurons in N7 have been reported to receive direct hypoglossal nerve input (28). This latter explanation is consistent with the fact that labeling in these nuclei was detected only after 24 hrs; however, this point was not further investigated.
- Together, the data summarized in Table 1 clearly establish transneuronal transport of the β-gal-TTC fusion protein from the hypoglossal neurons into several connected regions of the brainstem.
TABLE 1 Transneuronal transport of the lacZ-TTC fusion from the XII nerve: labeling of different cells types in the central nervous system. 12-18 24-48 Cell groups hrs hrs First order neurons First category: XII, hypoglossal motoneurons ++ +++ Second category: N7, facial nu − ++ Mo5, motor trigeminal nu − ++ Acs5, accessory trigeminal nu − + Second order cell groups MdD, medullary reticular nu, dorsal − ++ MdV, medullary reticular nu, ventral − +/− PCRt, parvicellular reticular nu, caudal − ++ PCRt, parvicellular reticular nu, rostral − ++ Sol, solitary tract nu − + DPGi, dorsal paragigantocellular nu − +/− PnC, pontine reticular nu, caudal − + RMc, magnocellular reticular nu − +/− R, caudal raphe nu − +/− MVe, medial vestibular nu − + IV, inferior vestibular nu − +/− LC, locus coeruleus − + Me5, mesencephalic trigeminal nu (*) − + CG, mesenphalic central gray (*) − +/−
(*) Represents second order cell groups that also contain putative third order neurons (see text).
−, no labeling;
+ to +++, increased density of label;
+/− weak labeling.
16 animals were analysed for the 12-18 hrs p.i. data;
6 animals were analysed for the 24-48 hrs p.i. data.
- In another embodiment of the invention, we have constructed a fusion protein (GFP-TTC) comprising the C-terminal fragment of tetanus toxin and the GFP reporter gene, and have demonstrated its effectiveness to map a simple neural network retrogradely and transsynaptically in transgenic mice. (Maskos et al., 2002). The GFP-TTC fusion protein permits the visualization of membrane traffic at the presynaptic level of the neuromuscular junction and can be detected opticaly without immunological or enzymatic reactions. The GFP-TTC fusion protein, therefore, permits observation of active neurons with minimal disturbance of their physiological activities.
- We have also previously shown that, without neural activity, localization of a TTC fusion protein at the NMJ is impaired (Miana-Mena et al., 2002). In this aspect of the invention, therefore, we investigated in vivo, the influence of neurotrophic factors on neuronal localization and internalization of GFP-TTC and the mechanisms by which certain neurotrophic factors influence neuronal trafficking in vivo. We found that localization of GFP-TRC at the NMJ is rapidly induced by neurotrophic factors such as Brain Derivated Neurotrophic Factor (BDNF), Neurotrophin 4 (NT-4), and Glial-Derived Neurotrophic Factor (GDNF) but not by Nerve Growth Factor (NGF), Neurotrophin 3 (NT-3), and Ciliary Neurotrophic Factor (CNTF).
- Co-injection of various amounts of BDNF with the GFP-TTC probe induces an increase of the fluorescence measured at the neuromuscular junction (NMJ). This effect, which is detectable as early as 5 min after injection and reaches a maximum level at about 30 min after injection, indicates that BDNF treatment enhances neuronal endocytosis. Among other functions, BDNF stimulates the secretion of neurotransmitter from Xenopus nerve muscle co-cultures and from hippocampal neurons (Lohof et al., 1993; Tyler and Pozzo-Miller, 2001). Since tetanus toxin is known to enter neurons by means of synaptic vesicle endocytosis (Matteoli et al., 1996), BDNF might increase GFP-TTC internalization through enhancement of synaptic vesicle turnover. In our study, BDNF effects persisted after BoTx/A treatment, which blocks exocytosis and endocytosis of synaptic vesicles, showing that BDNF increases the kinetics and localization of a TTC-containing fusion protein at the NMJ through another endocytic pathway. Therefore, intramuscular injection of GFP-TTC and visualization of transport mechanisms revealed at least two different endocytic pathways: a clathrin-dependent and a clathrin-independant pathways. We found that after intramuscular injection of GFP-TTC, it displayed characteristics consistent with localization in lipid rafts, including biochemical colocalization with
caveolin 3 and colocalization with GM1, a raft marker identified by CT-b binding (Orlandi and Fishman, 1998; Wolf et al., 1998). Accordingly, the clathrin-independent pathway used by GFP-TTC, appears to involve lipid microdomains. Analysis by confocal microscopy revealed morphologically two different labelings. Firstly, a GFP-TTC diffuse staining, which partially overlaps with the synaptic vesicle SV2 but also with the raft marker CT-b, indicating a mixing of synaptic vesicles and lipid rafts. Secondly, highly fluorescent domains, which are detected before and persist after the more diffuse pattern and that appear to be invaginations or infoldings of the synaptic membrane. These GFP-TTC patches contained only CT-b labeling. Indeed, lipid microdomains which play a role in cellular functions such as vesicular trafficking and signal transduction (Simons and Toomre, 2000), can move laterally and cluster into larger patches (Harder et al., 1998). They might also be specific zones of exocytosis in the presynaptic compartment, undergoing a rapid form of internal traffic in response to retrograde signaling from target cells. Similar infolding and cisternae structures have been described in frog motor nerve terminals which replesnish the pool of synaptic vesicles in a manner dependent upon neuronal activity (Richards et al., 2000). In CHO cells, tubular caveolae have also been described (Mundy et al., 2002). - Based on the kinetics of probes for NMJ localization, we observed different trafficking behaviours for GFP-TTC and CT-b. It has been postulated that targeting of toxin into the cell depends on the structure and function of endogenous ganglioside receptors, which could couple toxins to specific lipid raft microdomains (Wolf et al., 1998). Thus, in vivo, endogenous or injected BDNF might increase the amount of lipid microdomains containing TTC receptors. Tetanus toxin and cholera toxin bind to different gangliosides, known as GD1 b/GT1b and GM1, respectively. Hence, the difference we observed in the dynamics of recruitment at the presynaptic motor nerve terminal may be relevant to different lipid microdomains having specific glycosphingolipids and protein composition. Neuronal membranes are rich in gangliosides and different microdomains are likely to co-exist on the cell surface. Indeed, Thy-1 and PrP prion protein, two functionally different GPI proteins, are found in adjacent microdomains (Madore et al., 1999). Similarly, syntaxins are concentrated in cholesterol-dependent microdomains, which are distinct from rafts containing GPI-linked proteins (Lang et al., 2001).
- Like BDNF, NT4 was also found to increase the concentration of GFP-TTC at the NMJ, whereas NGF and NT-3 had no effect. Since the TrkB receptor is specifically activated by BDNF and NT4, TrkB activation might be involved in this neoronal trafficking. Interestingly, high-frequency neuronal activity and synaptic transmission have been shown to elevate the number of TrkB receptors on the surface of cultured hippocampal neurons (Du et al., 2000), apparently by recruiting extra TrkB receptors to the plasma membrane (Meyer-Franke et al., 1998). Moreover, TrkB is highly enriched in lipid microdomains from neuronal plasma membrane (Wu et al., 1997). However, no specific colocalization between GFP-TTC and TrkB or p-Trk receptors were detected at the NMJ. Thus, TrkB may act indirectly on the detected traffic at the presynaptic motor nerve membrane.
- It is worth noting that the TTC fragment has been detected in cultured motoneurons in the same vesicles as p75NTR (Lalli and Schiavo, 2002). This colocalization may be explained by the tight association of p75NTR, which is expressed mainly during development and in pathological conditions, with GT1b ganglioside (Yamashita et al., 2002). Binding of neurotrophins to their Trk receptors leads to phosphorylation of tyrosine residues that are recognized by several intracellular signaling proteins. Such interactions lead to the activation, by means of a kinase cascade, of the MAP kinase, PI 3-kinase and phospholipase-C-γ pathways (for review see (Huang and Reichardt, 2003)). Many of the intermediates in these signaling cascades are also present in lipid rafts (Simons and Toomre, 2000; Tsui-Pierchala et al., 2002). Activation of PKA is required for translocation of activated p75NTR to lipid rafts (Higuchi et al., 2003). Similarly, the coreceptor GFRα1, which binds GDNF and thus allows activation of the c-RET tyrosine kinase receptor, localize to lipid rafts. GFRα1 recruits RET to lipid rafts after GDNF stimulation and results in strong and continuous signal transduction (Paratcha et al., 2001; Tansey et al., 2000).
- Another neurotrophic factor, GDNF, also induced GFP-TTC localization at the NMJ. GDNF, however, activates a different receptor (i.e., a GFRα/cRET receptor) than BDNF and NT4. Because BDNF/NT-4 and GDNF activate different receptors, we postulated that component(s) of their activation pathways may activate the trafficking of GFP-TTC receptors in specific lipid microdomains. Indeed, various stimuli can lead to internalization of caveolae, a specialized form of lipid rafts. Thus,
simian virus 40 stimulates its internalization in caveolae and transport via caveosomes (Pelkmans et al., 2001). Similarly, the albumin-docking protein pg60 activates its transendothelial transport by interaction with caveolin-1 and subsequent activation of Src kinase signaling (Minshall et al., 2000). Recently, it has been reported that tetanus toxin can activate, through the TTC fragment, intracellular pathways involving Trk receptors, extracellular signal-regulated kinases (ERK) and protein kinase C isoforms (Gil et al., 2001; Gil et al., 2000; Gil et al., 2003). In this way, tetanus toxin could therefore autoactivate its neuronal endocytosis via an uncoated pathway rather than by clathrin-dependent pathway to avoid the lysosomal degradation. - Finally, we have demonstrated that GFP-TTC trafficking is regulated by neurotrophic factors. By visualization of GFP-TTC trafficking, our data show that BDNF can stimulate both clathrin-coated and uncoated endocytic pathways, presumably via TrkB activation. Since tetanus toxin, as other pathogens or toxins, uses constitutive mechanisms for its internalization and traffic in cells, we have been able to visualize with GFP-TTC, a physiological response to neurotrophic factors.
- This aspect of the invention is further discussed in the following examples.
- To determine the characteristics of the GFP-TTC distribution at the NMJ, a single injection of the GFP-TTC fusion protein was performed in the immediate vicinity of the Levator auris longus (LAL) muscle and at various times after the injection, the LAL was removed and examined as a whole mount. As LAL is a thin and flat muscle consisting of only a few layers of fibers, the entirety of the neuromuscular preparation with associated nerves could be examined by confocal analysis (
FIG. 6A ). As shown inFIG. 6 , GFP-TTC rapidly concentrates at the NMJ, as identified by the staining of muscle nicotinic acetylcholine receptors with TRITC-conjugated α-bungarotoxine (α-BTX). A patchy clustering of GFP-TTC was observed after approximately 5 min following the deposit of the fusion protein onto the surface of the LAL muscle (FIGS. 6D and D′). After 30 min, a more diffuse staining was observed that was distributed over the entire surface of the NMJ (FIGS. 6E and E′), and which persisted for about 2 h (FIGS. 6F and F′). Immunostaining experiments, performed with an anti body that recognizes troponin T confirmed that GFP-TTC is concentrated mainly in presynaptic motor nerve terminals of the NMJ (FIGS. 6C and C′). We could also detect a strong GFP-TTC labeling at the nodes of Ranvier of intramuscular myelinated axons and in sensory nerve fibers (FIGS. 6A and B; arrows and arrowheads respectively). It is likely that most of the GFP-TTC probe was internalized within 24 h, since only a few fluorescent patches persisted at the NMJ 24 h after its injection (FIGS. 6G and G′). - To assess whether exogenously applied neurotrophins affected GFP-TTC recruitment in motor nerve terminals, increasing concentrations of BDNF (2.5-250 ng) were co-injected with GFP-TTC in the vicinity of LAL muscles, while control mice were injected with GFP-TTC alone. Mice were sacrificed and LAL muscles harvested 30 min after injection. GFP fluorescence was quantified by confocal microscopy analysis at NMJs, after identification by TRITC-α-BTX labeling. BDNF injection produced a statistically significant concentration-dependent enhancement of GFP-TTC fluorescence at the NMJ, with the highest effect obtained with 50 ng BDNF (
FIG. 7B and Table 2) while higher doses (100 and 250 ng) resulted in weaker elevations in the level of GFP-TTC concentration at the NMJ (1.72±0.12 and 1.15±0.22 fold respectively). The higher GFP-TTC axonal labeling observed at these higher doses (FIG. 7A , arrows), probably correlates to an enhanced internalization of the probe. - In TrkB mutant mice, a physiological phenotype in the facial nerve nucleus, which innervates LAL muscle has been reported (Klein et al., 1993; Silas-Santiago et al., 1997). To exclude the possibility that the BDNF effect observed could be LAL specific, a different muscle, the gastrocnemius, was also analyzed. Thirty minutes after injecting GFP-TTC (±
BDNF 50 ng) in gastrocnemius, muscles were fixed, removed and serially sectioned. For each muscle, different serial sections were quantified for GFP-TTC fluorescence at the motor nerve terminals as described in material and methods. We found that the BDNF-dependent increase of GFP-TTC concentration at the NMJ, closely resembled that observed in LAL (1.51±0.12 fold increase vs 2.12±0.19 respectively). - We also examined the effect of five additional trophic factors on GFP-TTC localization at the NMJ, including the neurotrophins NT-3; NT-4 and NGF as well as the neurocytokine CNTF (Ciliary Neurotrophic Factor), a member of the LIF cytokine family, and GDNF (Glial-Derivated Neurotrophic Factor), a member of the TGF-β superfamily (Table 2). Many BDNF actions in neurons are mediated via the high affinity receptor tyrosine kinase TrkB, which is also the receptor for NT-4. Like BDNF, NT-4 also induced GFP-TTC localization at the NMJ (a 1.54±0.23 fold increase). A level of induction similar to NT-4 was also observed for GDNF (Table 2). On the other hand, even at high concentrations, neither NGF, NT-3, nor CNTF exhibited a significant effect on GFP-TTC localization.
TABLE 2 Effect of various neurotrophic factors on nerve terminal's GFP- fluorescence level 30 min after in vivo GFP-TTC injection.Relative increase Receptor in fluorescence level BDNF TrkB 2.12 ± 0.19 ** NT-4 TrkB 1.49 ± 0.23 ** NT-3 TrkC 0.94 ± 0.05 NGF TrkA 1.06 ± 0.06 CNTF CNTFRα 0.95 ± 0.05 GDNF GFRα/cRET 1.51 ± 0.02 *
GFP-TTC was co-injected with increasing concentrations of neurotrophic factors and GFP fluorescence quantified 30 min after as previously described. Mean of relative increase of GFP fluorescence of 2 or 3 independent experiments are indicated. Maximum fold induction was obtained for 50 ng of neurotrophic factor injected except for NT-3 (2.5 ng).
** P < 0.005;
* P < 0.05 t-test vs control.
- Detection of either TrkB mRNA or protein in adult skeletal muscle and motoneurons has been reported in several studies (Funakoshi et al., 1993; Gonzalez et al., 1999; Griesbeck et al., 1995; Yan et al., 1997). Since our results indicated that the BDNF effect on GFP-TTC localization is dependent on TrkB receptor activation, it was of interest to determine whether GFP-TTC colocalized with TrkB at the NMJ of LAL muscles. Consistent with previous studies (Gonzalez et al., 1999; Sakuma et al., 2001), TrkB immunostaining was confined to the NMJ (
FIG. 8 ). In the presynaptic side, TrkB staining was adjacent to, but not colocalized to the clusters of GFP-TTC labeling. Similar results were also obtained with an antibody that recognizes the activated Trk receptors (p-Trk, data not shown). This observation suggests that the mechanism whereby BDNF has an influence on the concentration of GFP-TTC at the nerve terminals, does not involve a direct interaction between TrkB and GFP-TTC or its receptors. - Possible explanations for the BDNF-induced enrichment of GFP-TTC at the NMJ could involve an elevated rate of localization of the probe at the NMJ, and/or an increased neuronal endocytosis of the probe. Confocal analysis performed 5, 15, 30, 60 and 120 min after GFP-TTC injection (+
BDNF 50 ng) showed maximal labeling intensity at 30 min with BDNF injection, whereas in controls, the maximal staining occurred at 1 h and reached a level lower than that obtained with BDNF co-injection. After the first hour, similar levels of GFP-TTC were recorded at the NMJ in both conditions (FIG. 9A ). These results are in accordance with previous results in Xenopus nerve-muscle co-culture indicating a time-limiting effect of BDNF (Lohof et al., 1993). - In vitro, tetanus neurotoxin internalization in neurons appears to involve both coated and uncoated-vesicular pathways (Herreros et al., 2001; Matteoli et al., 1996). Experiments performed either in vitro on excised LAL muscles with the endocytic fluid marker RH414 (data not shown), or immunostained against the SV2 synaptic vesicle proteins (
FIG. 9B ) and synaptophysin (data not shown) showed some overlapping with GFP-TTC labeling, indicating that the endocytosis of GFP-TTC was in part via recycling of neuronal synaptic vesicles. To differentiate between clathrin-dependent and clathrin-independent endocytic pathways, we used treatment with botulinum neurotoxin serotype A (BoTx/A), which blocks neurotransmitter release and endocytosis in motor nerve terminals (de Paiva et al., 1999). When BoTx/A was applied 48 hours before GFP-TTC injection, the probe level at the NMJ was markedly decreased by 50% (FIG. 9C ), indicating that both clathrin-dependent and independent pathways are used to a comparable degree. - Enhanced synaptic transmission produced by application of exogenous BDNF; NT-3 or NT4 involves a potentiation of neurotransmitter release (Lohof et al., 1993; Stoop and Poo, 1996; Wang and Poo, 1997). The increasing amount of GFP-TTC at the NMJ induced by BDNF injection could therefore be due in part to an elevated recycling of synaptic vesicles. To explore this hypothesis, increased exocytosis and endocytosis of synaptic vesicles were induced by GFP-TTC injection in a high-potassium medium. Five minutes after injection, exposure to high K+ medium or BDNF induced a similar increase of GFP-TTC level at the NMJ. However, after 30 min, the effect of high K+ was no longer detectable, whereas maximal induction was reached with BNDF at this time (
FIG. 9D ). Finally, even after neurotransmitter release and synaptic vesicle recycling were blocked by BoTx/A, an increased GFP-TTC signal was induced by BDNF treatment (FIG. 9C ) with an amplitude comparable to that recorded in the non-paralyzed control NMJ (2.05 fold increase vs 2.12 respectively). Taken together, these results indicate that BDNF enhances an alternative endocytic pathway that appears to involve uncoated vesicles. - Binding of TTC to plasma membranes involves association to polysialogangliosides GD1 b and GT1b, as well as a N-glycosylated 15 kDa protein. These three components partition preferentially in membrane microdomains called rafts. In vitro, TTC has been shown to associate with such microdomains in NGF-differentiated PC12 cells and in cultured spinal cord neurons (Herreros et al., 2001 Vyas, 2001). To test in vivo whether GFP-TTC associated to lipid rafts, gastrocnemius muscles were submitted to detergent extraction to isolate lipid microdomains after GFP-TTC intramuscular injection. Twelve fractions from the discontinuous sucrose gradient were collected and analyzed for distribution of GFP-TTC.
- Neurons do not contain caveolin or morphologically distinct caveolae (Anderson, 1998), but significant fractions of cholesterol and glycosphingolipids are found in detergent-insoluble complexes, which are indistinguishable using the criteria of detergent insolubility from those associated with caveolae (Schnitzer et al., 1995). Thus,
caveolin 3, a specific muscular caveolar marker (Tang et al., 1996), was used to identify the detergent-resistant fractions. Immunoblot analysis revealed that GFP-TTC co-migrated with raft microdomains, which contain caveolin 3 (FIG. 10A ). - To investigate whether the GFP-TTC patches observed in vivo in motor nerve terminals correspond to lipid microdomains, we performed co-staining with Alexa 594-conjugated cholera toxin-B fragment (CT-b). CT-b specifically binds to ganglioside GM1, which is enriched in cholesterol-rich membrane microdomains, and is commonly used as a marker for membrane rafts and caveolae (Orlandi and Fishman, 1998; Schnitzer et al., 1995; Wolf et al., 1998). GFP-TTC and Alexa 594-conjugated CT-b fragment were co-injected into the gastrocnemius and confocal analysis was performed 1; 3; 5; 9 and 24 h later, with the NMJ being identified by AlexaFluor 647-conjugated α-BTX (
FIG. 10B ). Although the GFP-TTC labeling of motor nerve terminals was easily visualized in less than the 5 min necessary to process the tissue (FIGS. 6D and D′), CT-b was detectable at the NMJ only several hours after injection (3-5 h). Thus, the dynamics of trafficking of CT-b and TTC receptors to active synapse are clearly different. However, after 5 h, the distribution obtained for CT-b was similar to GFP-TTC staining, as characterized by diffuse staining and patches having an extensive overlap of the staining patterns obtained with GFP-TTC, indicating a localization of the TTC probe in lipid microdomains in motor nerve endings (FIG. 10B ). Twenty four hours after gastrocnemius injection, both toxins had been internalized since only few patches, most of them positive for both toxins, persisted at the NMJ (FIGS. 10B and C). At this time, GFP-TTC and CT-b staining were detected in the same motoneuron cell bodies in the ventral horn of the spinal cord, but in different vesicular compartments (FIG. 11 ). Taken together, these results indicate that GFP-TTC used different lipid microdomains for neuronal binding and/or internalization pathways than CT-b. - Materials and Methods
- Antibodies and Reagents.
- Rabbit anti-GFP polyclonal antibodies was obtained from Invitrogen (1:5000 dilution). Mouse monoclonal antibody against
caveolin 3 was from Transduction Laboratories (1:500). The monoclonal anti-neurofilament 200 (clone NE14) and the rabbit polyclonal antitroponin T were obtained from Sigma. AlexaFluor 594-conjugated Cholera toxin subunit B (CT-b); AlexaFluor 488-conjugated goat-antirabbit IgG, AlexaFluor 647-conjugated α-bungarotoxin (α-BTX) and RH414 were obtained from Molecular Probes. Cy3-conjugated goat anti-rabbit IgG and Cy3-conjugated rat anti-mouse IgG were from Jackson Laboratories. TRITC-conjugated α-bungarotoxin was obtained from Calbiochem. The rabbit anti-TrkB (794) and the anti-p-Trk polyclonal antibody were obtained from SantaCruz. The monoclonal antibody against synaptic vesicle protein SV2, developed by K. Buckley, was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biological Sciences, Iowa City. Monoclonal antibody against synaptic vesicle synaptophysin protein was obtained from Chemicon. The goat anti-rabbit and anti-mouse IgG antibodies conjugated to horseradish peroxydase were obtained from Pierce as well as the SuperSignal detection reagent. Recombinant neurotrophic factors rat CNTF; human NT3; human NT4, human BDNF, human GDNF and purified mouse NGF 7S were purchased from Alomone labs. Neurotrophic factors were prepared as stock solutions (10 μg/ml) and kept in aliquots at −80° C. - In Vivo Intramuscular Injection.
- Experiments were performed in accordance with French and European Community guidelines for laboratory animal handling. Six-week-old Swiss female mice were obtained from Charles River Breeding Laboratories. Intramuscular injections of β-gal-TTC, GFP-TTC fusion proteins, produced as previously described (Coen et al., 1997), or AlexaFluor 594-conjugated CT-b were intramuscular injected into the gastrocnemius muscle or subcutaneously in the immediate vicinity of the Levator auris longus (LAL) muscle on anesthetized mice. For fluorescence quantification, 25 μg of GFP-TTC fusion protein were injected in PBS in 50 μl final volume. For immunodetection or biochemical extraction, 50 μg of GFP-TTC probe were used. When co-injections with neurotrophic factors were performed, the volume injected was kept constant (50 μl). For injection in high K+, a physiological solution containing 60 mM KCl was co-injected with the probe.
- Botulinum type-A Toxin Injection.
- Clostridium botulinum type-A toxin (BoTx/A) was injected subcutaneously as a single dose of 0.05 ml containing about 0.5 pg of the purified neurotoxin in the vicinity of the LAL muscle of female Swiss mice (body weight 24-27 g). 48 h after BoTx/A treatment, a time sufficient for inducing muscle paralysis in the LAL due to blockade of neurotransmitter release (de Paiva et al., 1999), GFP-TTC (25 μg) was injected associated or not with BDNF (50 ng) in the vicinity of the LAL muscle. Mice were killed by intracardial injection of
PFA 4% 30 min after injection and LAL muscle harvested and processed for confocal analysis. - In vitro analysis of GFP-TTC localization and confocal acquisition.
- LAL muscles with their associated nerves were isolated from female Swiss-Webster mice (20-25 g), killed by dislocation of the cervical vertebrae. LAL muscles were mounted in Rhodorsil®-lined organ baths (2 ml volume) superfused with a standard oxygenated physiological solution of the following composition (mM): NaCl 154;
KCl 5;CaCl 2 2;MgCl 2 1; HEPES buffer 5 (pH=7.4) andglucose 11. Muscles were loaded for 45 min in the dark and at room temperature with both 25 μg GFP-TTC and 30 μM of RH414, dissolved in standard solution or, for synaptic vesicle recycling, in high K+ isotonic solution (with 60 mM KCl replacing 60 mM NaCl). Preparations were washed out of the GFP-TTC and RH414 dye, and rinsed several times with dye-free standard medium before being imaged with a Leica TCS SP2 confocal laser scanning microscope system (Leica Microsystems, Germany) mounted on a Leica DM-RXA2 upright microscope equipped with a x40 water immersion lens (Leica, NA 0.8). The confocal system was controlled through Leica-supplied software running on a Windows NT workstation. - Preparation of Detergent-Resistant Membrane(DRMs) fractions and Western Blot
- Preparation of detergent-resistant membrane fractions is one of the most widely used methods for studying lipid rafts. Two hours after GFP-TTC injection (50 μg), mouse gastrocnemius muscle tissue was harvested, minced with scissors and homogenized in 2 ml of MES-buffered saline containing 1% (v/v) Triton X-100. Homogenization was carried out with a Polytron tissue grinder. After centrifugation at low speed for 5 min, supernatant was adjusted to 40% sucrose. A 5-30% linear sucrose gradient was formed above the homogenate and centrifuged at 39,000 rpm for 18 h in a SW41 rotor. Then, 11-12 fractions of 1 ml were collected from the top of the gradient and precipitated with 6.5% trichloroacetic acid in the presence of 0.05% sodium deoxycholate and washed with 80% cold acetone. Samples were analyzed by Western Blot after separating on a 4-15% SDS-PAGE followed by Western Blot. Membranes were probed first with polyclonal anti-GFP and
monoclonal anti-caveolin 3 antibodies, and then incubated with goat anti-rabbit IgGs and goat anti-mouse IgGs antibodies conjugated with horseradish peroxydase. The SuperSignal (Pierce) was used to visualize the reaction - Quantification of GFP-TTC Fluorescence Intensity at the NMJ.
- After intracardiac perfusion and fixation, LAL muscles were harvested, washed in PBS for 20 min, stained with TRITC-conjugated a-bungarotoxin (TRITC-a-BTX) (2 μg/ml) for 45 min at 37° C. in PBS and washed twice in PBS. Images were acquired on an Axiovert 200M laser scanning confocal microscope (LSM-510 Zeiss; version 3.2) through a ×40/1.2 water-immersion objective using LP560 and BP505-550 filters. The pinhole aperture was set to 1 airy unit, and images were digitized at 8-bit resolution into a 512×512 pixel array. To be able to compare the intensity of GFP staining between different experiments, laser illumination, photomultiplier gain in regard of linear response, and other acquisition variables were standardized. To quantify GFP-TTC localization at the NMJ, series of “look-through” projection (of MIP: Maximum Intensity Projection) was generated. Images from each NMJ were processed identically: NMJ surface area (in μm2) was determined by TRITC-a-BTX labeling and GFP fluorescence global intensity (sum of each pixel intensity) was then measured only in this predefined area. This value, divided by the NMJ area yielded GFP fluorescence intensity per square micrometer, which thus defined the fluorescence level expressed as arbitrary units. For each condition, ˜15 to 20 synapses were quantified and results were expressed as the mean±SD. Statistical significance was defined as p<0.05 using a two-tailed t test. Each experiment was repeated at least two or three times.
- Analysis of Spinal Cord.
- 24 hours after β-gal-TTC or GFP-TTC and CT-b injection into the gastrocnemius muscle (50 μg each), mice deeply anesthetized were perfused intracardially with 4% PFA. The spinal cord was harvested and embedded in Tissue Tek embedding media after overnight incubation in 25% sucrose in PBS 0.1M. Longitudinal cryostat sections (30 μm thickness) were cut and mounted onto coated slides.
- X-gal Reaction.
- X-gal reaction was performed as previously described (Coen et al., 1997).
- The following publications, which have been cited herein, are relied upon and incorporated by reference in their entireties herein.
- 1. Eisel, U., Jarausch, W., Goretzki, K., Henschen, A., Engels, J., Weller, U., Hudel, M., Habermann, E. & Niemann, H. (1986) EMBO J. 5, 2495-2502.
- 2. Fairweather, N. F. & Lyness, V. A. (1986) Nucleic Acids Res. 14, 7809-7812.
- 3. Montecucco, O. & Schiavo, G. (1995) Quart. Rev. Biophys. 28, 423-472.
- 4. Schwab, M. E. & Thoenen, H. (1976) Brain Res. 105, 213-227.
- 5. Schwab, M. E. & Thoenen, H. (1977) Brain Res. 122, 459-474.
- 6. Price, D. L., Griffin, J. W. & Peck. K. (1977) Brain Res. 121, 379-384.
- 7. Bizzini, B., Stoeckel, K. & Schwab, M. (1977) J. Neurochem. 28, 529-542.
- 8. Evinger, O. & Erichsen, J. T. (1986) Brain Res. 380, 383-388.
- 9. Fishman, P. S. & Carrigan, D. R. (1987) Brain Res. 406, 275-279.
- 10. Manning, K. A., Erichsen, J. T. & Evinger, O. (1990) Neurosci. 34, 251-263.
- 11. Halpern, J. L., Habig, W. H., Neale, E. A. & Stibitz, S. (1990) Infection and Immunity 58, 1004-1009.
- 12. Bizzini, B., Grob, P., Glicksman, M. A. & Akert, K. (1980) Brain Res. 193, 221-227.
- 13. Dobrenis, K., Joseph, A. & Rattazzi, M. G. (1992) Proc. Natl. Acad. Sci. USA 89, 2297-2301.
- 14. Fishman, P. S. & Savitt, J. M. (1989) Exp. Neurol. 106, 197-203.
- 15. Beaude, P., Delacour, A., Bizzini, B., Domuado, D. & Remy, M. H. (1990) Biochem. 271, 87-91.
- 16. Francis, J. W., Hosler, B. H., Brown, R. H., Jr. & Fishman, P. S. (1995) J. Biol. Chem. 270, 15434-15442.
- 17. Fellous. M., Gunther, E., Kemler, R., Weils, J., Berger, R., Guenet, J. L., Jakob, H. & Jacob, F. (1978) J. Exp. Med. 148, 58-70.
- 18. Jakob, H. & Nicolas, J. F. (1987) Methods Enzymol 151, 66-84.
- 19. Whitehouse, R. L. S., Benichou, J. O. & Ryter, A. (1977) Biol. Cell. 30, 155-158.
- 20. Wojcik, B. E., Nothias, F., Lazar, M., Jouin, H., Nicolas, J. F. & Peschanski, M. (1993) Proc. Natl. Acad. Sci. USA 90, 1305-1309.
- 21. Price, D. L., Griffin, J. Young, A. Peck, K & Stocks, A. (1975) Science 188, 945-947.
- 22. Matteoli, M., Verderio, C., Rossetto, O., Iezzi, N., Ooco. S. Schiavo, G. & Montecucco, G, (1996) Proc. Natl. Acad. Sci. USA 93, 13310-13315.
- 23. Stockel, K., Schwab, M. & Thoenen, H. (1975) Brain Res. 99, 1-16.
- 24. Ugolini, G. (1995a) in Viral Vectors: Gene Therapy and Neuroscience Applications, eds. Loewy, A. D. & Kaplitt M. G. (New York: Academic Press), pp. 293-317.
- 25. Ugolini, G. (1995b) The Journal of Comparative Neurology 356, 457-480.
- 26. Borke, R. C., Nau, M. E. & R. L Ringler, J. (1983) Brain Research 269, 47-55.
- 27. Horst, G. T. T., Copray, J. C. V. M., liem, R. S. B. & Willigen, J. D. V. (1991)
Neuroscience 40, 735-758. - 28. O'Reilly, P. M. R. & Fitzgerald, M. J. T. (1990) J. Anat. 172, 227-243.
- 29. Chalfie, M. Tu, Y., Euskirchen, G., Ward, W. W. & Prasher, D. C. (1994) Science 263, 802-805.
- 30. Miesenböck, G. & Rothman, J. E. (1997) Proc. Natl. Acad. Sci. USA 94, 3402-3407.
- 31. Le Mouellic, H., Lallemand, Y. & Brûlet, P. (1990) Proc. Natl. Acad. Sci. USA 87, 4712-4716.
- 32. Le Mouellic, H., Lallemand, Y. & Brûlet, P. (1992) Cell 69, 251-264.
- 33. Mombaerts, P., Wang, F., Dulac, C. Chao, S. K., Nemes, A., Mendelsohn, M., Edmondson, J. & Axel, R. (1996) Cell 87, 675-686.
- 34. Mounfford, P. S. & Smith, A. G. (1995) Trends Genet. 11, 179-184.
- 35. Rosen, D. R. & al (1993) Nature 362, 59-62.
- 36. Lefebvre, S., Büglen, L., Reboullet, S. Clermont, O., Bûrlet, P., Viollet, L, Benichou, B., Cruaud, O., Millasseau, P., Zeviani, M., Paslier, D. L., Frézal, J., Cohen, D., Weissenbach, J., Munnich, A. & Melki, J. (1995)
Cell 80, 155-165. - 37. Roy, N. & al (1995)
Cell 80, 167-178. - 38. Wolfe, J. H., Deshmane, S. L. & Fraser, N. W. (1992) Nature genetics. 1, 379-384.
- 39. Sango, K., Yamanaka, S., Hoffmann, A., Okuda, Y., Grinberg, A., Westphal, H., McDonald, M. P., Crawley, J. N., Sandhoff, K., Suzuki, K. & Proia, R. L. (1995)
Nature Genetics 11, 170-176. - 40. Duarte, R. G. (1995)
Neurologia 1, 56-61. - 41. Ghadge, G. D., Roos, R. P., Kang, U. J., Wollmann, R., Fishman, P. S., Kalynych, A M., Barr, E. & Leiden, J. M. (1995)
Gene Therapy 2, 132-137. - Anderson, R. G. W. 1998. The caveolae membrane system. Annu. Rev. Biochem. 67:199-225.
- Bothwell, M. 1995. Functionnal interactions of neurotrophins and neurotrophin receptors. Annu. Rev. Neurosci. 18:223-225.
- Coen, L., R. Osta, M. Maury, and P. Brûlet. 1997. Construction of hybrid proteins that migrate retrogradely and transynaptically into the central nervous system. Proc. Natl. Acad. Sci. USA. 94:9400-9405.
- de Paiva, A. M., F. A. Meunier, J. Molgo, R. Aoki, and J. O. Dolly. 1999. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. USA. 96:3200-3205.
- Du, J., L. Feng, F. Yang, and B. Lu. 2000. Activity and Ca2+-dependent modulation of surface expression of brain-derived neurotrophic factor receptors in hippocampal neurons. J. Cell Biol. 150:1423-1434.
- Funakoshi, H., N. Belluardo, E. Arenas, Y. Yamamoto, A. Casabona, H. Persson, and C. F. Ibanez. 1995. Muscle-derived neurotrophin-4 as an activity-dependent trophic signal for adult motor neurons. Science. 268:1495-1499.
- Funakoshi, H., J. Frisen, G. Barbany, T. Timmusk, O. Zachrisson, V. M. K. Verge, and H. Persson. 1993. Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve. J. Cell Biol. 123:455-465.
- Gil, C., I. Chaib, J. Blasi, and J. Aguilera. 2001. Hc fragment of tetanus toxin activates protein kinase C isoforms and phosphoproteins involved in signal transduction. Biochem. J. 356:97-103.
- Gil, C., I. Chaib, P. Pellicioni, and J. Aguilera. 2000. Activation of signal transduction pathways involving TrkA, PLCγ, PKC isoforms and ERK-1/2 by tetanus toxin. FEBS. 481:177-182.
- Gil, C., I. Chaib-Oukadour, and J. Aguilera. 2003. C-terminal fragment of tetanus toxin heavy chain activates Akt and MEK/ERK signaling pathways in a Trk receptor-dependent manner in cultured cortical neurons. Biochem. J. 373:613-620.
- Gonzalez, M., F. P. Ruggiero, Q. Chang, Y.-J. Shi, M. M. Rich, S. Kraner, and R. J. Balice-Gordon. 1999. Disruption of TrkB-mediated signaling induces disassembly of postsynaptic receptor clusters at neuromuscular junction. Neuron. 24:567-583.
- Griesbeck, O., A. S. Parsadenian, M. Sendtner, and H. Thoenen. 1995. Expression of neurotrophins in skeletal muscle: quantitative comparison and significance for motoneuron survival and maintenance of function. J. Neurosci. Res. 42:21-33.
- Harder, T., P. Scheiffele, P. Verkade, and K. Simons. 1998. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J. Cell Biol. 141:929-942.
- Herreros, J., T. Ng, and G. Schiavo. 2001. Lipid rafts act as specialized domains for tetanus toxin binding and internalization into neurons. Mol. Biol. Cell. 12:2947-2960.
- Higuchi, H., T. Yamashita, H. Yoshikawa, and M. Tohyama. 2003. PKA phosphorylates the p75 receptor and regulates its localization to lipid rafts. Embo J. 22:1790-1800.
- Huang, E. J., and L. F. Reichardt. 2003. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 72:609-642.
- Klein, R., R. J. Smeyne, W. Wurst, L. K. Long, A. B. A, A. L. Joyner, and M. Barbacid. 1993. Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lessions and neonatal death. Cell. 75:113-122.
- Lalli, G., and G. Schiavo. 2002. Analysis of retrograde transport in motor neurons reveals common endocytic carriers for tetanus toxin ans neurotrophin receptor p75NTR . J. Cell Biol. 156:233-239.
- Lang, T., D. Bruns, D. Wenzel, D. Riedel, P. Holroyd, C. Thiele, and R. Jahn. 2001. SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. Embo J. 20:2202-2213.
- Lohof, A. M., N.Y. Ip, and M. M. Poo. 1993. Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF. Nature. 363:350-353.
- Madore, N., K. L. Smith, C. H. Graham, A. Jen, K. Brady, S. Hall, and R. Morris. 1999. Functionally different GPI proteins are organized in different domains on the neuronal surface. Embo J. 18:6917-6926.
- Maskos, U., K. Kissa, C. Saint Clonnent, and P. Brûlet 2002. Retrograde trans-synaptic transfer of green fluorescent protein allows the genetic mapping of neuronal circuits in transgenic mice. Proc. Natl. Acad. Sci. USA. 95:10120-10125.
- Matteoli, M., C. Verderio, O. Rossetto, N. Iezzi, S. Coco, G. Schiavo, and C. Montecucco. 1996. Synaptic vesicle endocytosis mediates the entry of tetanus neurotoxin into hippocampal neurons. Proc. Natl. Acad. Sci. USA. 93:13310-13315.
- McAllister, A. K., L. C. Katz, and D. C. Lo. 1999. Neurotrophins and synaptic plasticity. Annu. Rev. Neurosci. 22:295-318.
- Meyer-Franke, A., G. A. Wilkinson, A. Kruttgen, M. Hu, E. Munro, M. G. J. Hanson, L. F. Reichardt, and B. A. Barres. 1998. Depolarization and CAMP elevation rapidly recruit TrkB to the plasma membrane of CNS neurons. Neuron. 21:681-693.
- Miana-Mena, F. J., S. Roux, J.-C. Benichou, R. Osta, and P. Brulet. 2002. Neuronal activity-dependent membrane traffic at the neuromuscular junction. Proc. Natl. Acad. Sci. USA. 99:3234-3239.
- Minshall, R. D., C. Tiruppathi, S. M. Vogel, W. D. Niles, A. Gilchrist, H. E. Hamm, and A. B. Malik. 2000. Endothelial cell-surface gp60 activates vesicle formation, and trafficking via Gi-coupled Src kinase signaling pathway. J. Cell Biol. 150:1057-1069.
- Mundy, D. I., T. Machleidt, Y. S. Ying, R. G. W. Anderson, and G. S. Bloom. 2002. Dual control of caveolar membrane traffic by microtubules and the actin cytoskeleton. J. Cell Science. 115:4327-4339.
- Orlandi, P. A., and P. H. Fishman. 1998. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domain. J. Cell Biol. 141:905-915.
- Paratcha, G., F. Ledda, L. Baars, M. Coulpier, V. Besset, J. Anders, R. Scott, and C. F. Ibanez. 2001. Released
GFRalpha 1 potentiates dowstream signaling, neuronal survival, and differenciation via a novel mechanism of recruitment of c-Ret to lipid rafts. Neuron. 29:171-184. - Pelkmans, L., J. Kartenbeck, and A. Helenius. 2001. Caveolar endocytosis of
simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat. Cell Biol. 3:473-483. - Poo, M. M. 2001. Neurotrophins as synaptic modulators. Nature Rev. Neurosci. 2:24-32.
- Richards, D. A., C. Guatimosim, and W. J. Betz. 2000. Two endocytic recycling routes selectively fill two vesicle pools in frog motor nerve terminals. Neuron. 27:551-559.
- Sakuma, K., K. Watanabe, M. Sano, I. Uramoto, H. Nakano, Y.-J. Li, S. Kaneda, Y. Sorimachi, K. Yoshimoto, M. Yasuhara, and T. Totsuka. 2001. A possible role for BDNF, NT-4 and TrkB in the spinal cord and muscle of rat subjected to mechanical overload, bupivacaine injection and axotomy. Brain Res. 907:1-19.
- Schnitzer, J. E., D. P. McIntosh, A. M. Dvorak, J. Liu, and P. Oh. 1995. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science. 269:1435-1439.
- Silas-Santiago, I., A. M. Fagan, M. Garber, B. Fritzsch, and M. Barbacid. 1997. Severe sensory deficits but normal CNS development in newborn mice lacking TrkB and TrkC tyrosine protein kinase receptors. Eur. J. Neurosci. 9:2045-2056.
- Simons, K., and D. Toomre. 2000. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1:31-40.
- Stoop, R., and M. M. Poo. 1996. Synaptic modulation by neurotrophic factors:differential and synergistic effects of brain-derived neurotrophic factor and ciliary neurotrophic factor. J. Neurosci. 16:3256-3264.
- Tang, Z. L., P. E. Scherer, T. Okamoto, K. Song, C. Chu, D. S. Kohtz, I. Nishimoto, H. F. Lodish, and M. P. Lisanti. 1996. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J. Biol. Chem. 271:2255-2261.
- Tansey, M., R. H. Baloh, J. Milbrandt, and E. M. J. Johnson. 2000. GFRα mediated localization of RET to lipid rafts is required for effective downstream signaling, differenciation and neuronal survival. Neuron. 25:611-623.
- Tao, H. W., and M. M. Poo. 2001. Retrograde signaling at central synapses. Proc. Nat. Acad. Sci. USA. 98:11009-11015.
- Tsui-Pierchala, B. A., M. Encinas, J. Milbrandt, and E. M. J. Johnson. 2002. Lipid raft in neuronal signaling and function. Trends Neurosci. 25:412-417.
- Tyler, W. J., and L. D. Pozzo-Miller. 2001. BDNF enhances quantal neurotransmitter release and increases the number of docked vesicles at the active zones of the hippocampal excitatory synapses. J. Neurosci. 21:4249-4258.
- Vyas. 2001. Segregation of gangliosides GM1 and GD3 on cell membranes, isolated membrane rafts and defined supported lipid monolayers. Biol. Chem. 382:241-250.
- Wang, X. H., and M. M. Poo. 1997. Potentiation of developing synapses by postsynaptic release of neurotrophin-4. Neuron. 19:825-835.
- Wolf, A. A., M. G. Jobling, S. Wimer-Mackin, M. Ferguson-Maltzman, J. L. Madara, R. K. Holmes, and W. I. Lencer. 1998. Ganglioside structure dictates signal transduction by cholera toxin and association with caveolae-like membrane domains in polarized epithelia. J. Cell Biol. 141:917-927.
- Wu, C., S. Butz, Y. Ying, and R. G. W. Anderson. 1997. Tyrosine kinase receptors concentrated in caveolae-like domains from neuronal plasma membrane. J. Biol. Chem. 272:3554-3559.
- Xie, K., T. Wang, P. Olafsson, K. Mizuno, and B. Lu. 1997. Activity-dependent expression of NT-3 in muscle cells in culture: implications in the development of neuromuscular junctions. J. Neurosci. 17:2947-2958.
- Yamashita, T., H. Higuchi, and M. Tohyama. 2002. The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. J. Cell Biol. 157:565-570.
- Yan, Q., M. J. Radeke, D. R. Matheson, J. Talvenheimo, A. A. Welcher, and P. Feinstein. 1997. Immunocytochemical localization of trkB in the central nervous system of the adult rat. J. Comp. Neurol. 378:135-157.
Claims (65)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/623,776 US20100260758A1 (en) | 1997-08-14 | 2009-11-23 | In vivo modulation of neuronal transport |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/662,808 US7923216B2 (en) | 1997-08-14 | 2003-09-16 | In vivo modulation of neuronal transport |
PCT/EP2004/010991 WO2005025592A2 (en) | 2003-09-16 | 2004-09-15 | In vivo modulation of neuronal transport |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/010991 Continuation WO2005025592A2 (en) | 1997-08-14 | 2004-09-15 | In vivo modulation of neuronal transport |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/623,776 Continuation US20100260758A1 (en) | 1997-08-14 | 2009-11-23 | In vivo modulation of neuronal transport |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060275327A1 true US20060275327A1 (en) | 2006-12-07 |
Family
ID=34312741
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/662,808 Expired - Fee Related US7923216B2 (en) | 1997-08-14 | 2003-09-16 | In vivo modulation of neuronal transport |
US11/375,093 Abandoned US20060275327A1 (en) | 1997-08-14 | 2006-03-15 | In vivo modulation of neuronal transport |
US12/623,776 Abandoned US20100260758A1 (en) | 1997-08-14 | 2009-11-23 | In vivo modulation of neuronal transport |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/662,808 Expired - Fee Related US7923216B2 (en) | 1997-08-14 | 2003-09-16 | In vivo modulation of neuronal transport |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/623,776 Abandoned US20100260758A1 (en) | 1997-08-14 | 2009-11-23 | In vivo modulation of neuronal transport |
Country Status (3)
Country | Link |
---|---|
US (3) | US7923216B2 (en) |
EP (1) | EP1663286B1 (en) |
WO (1) | WO2005025592A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090324549A1 (en) * | 2007-01-29 | 2009-12-31 | Fondazione I.R.C.C.S. Istituto Neurologico "Carlo Besta" | Proteins and/or peptides for the prevention and/or treatment of neurodegenerative diseases |
US20110002914A1 (en) * | 1997-08-14 | 2011-01-06 | Institut Pasteur | Hybrid tetnus toxoid proteins that migrate retrogradely and transynaptically into the cns |
WO2011066285A2 (en) * | 2009-11-24 | 2011-06-03 | Oregon Health & Science University | Peptide-based treatment for neurodegenerative diseases |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7923015B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
US7923216B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
GB0205376D0 (en) * | 2002-03-07 | 2002-04-24 | Royal Holloway University Of L | Spore germination |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
WO2005082096A2 (en) * | 2004-02-24 | 2005-09-09 | Allergan, Inc. | Botulinum toxin screening assays |
GB2431348B (en) * | 2004-06-23 | 2009-12-30 | Ian A Ferguson | Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders |
DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
KR20080090408A (en) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | Anti-abeta; globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
ES2332628B1 (en) * | 2007-10-05 | 2011-01-24 | Universidad De Zaragoza | USE OF THE CODING SEQUENCE OF THE CARBOXYL TERMINAL OF THE HEAVY CHAIN OF THE TETANIC TOXIN AS A MEDICINAL PRODUCT. |
US8173768B2 (en) * | 2009-07-13 | 2012-05-08 | Centre National De La Recherche Scientifique | Peptides having antimicrobial and neurotrophic activity and uses thereof |
JP2013523182A (en) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | Amyloid beta-binding protein |
CN105348387B (en) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | Amyloid beta binding proteins |
JP2017521408A (en) | 2014-07-02 | 2017-08-03 | スフェリウム バイオメッド エス.エル. | Method for increasing muscle mass using non-toxic tetanus toxin C fragment (TTC) |
CN105553844B (en) * | 2015-12-31 | 2018-12-14 | 北京华为数字技术有限公司 | A kind of transmission method and the network equipment of Link State Notification |
CN114163535A (en) * | 2021-11-09 | 2022-03-11 | 湖北科技学院 | Inducible expression of fusion protein using TTC as neuron cell targeting gene |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4479940A (en) * | 1981-01-22 | 1984-10-30 | Institut Pasteur | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications |
US4594336A (en) * | 1982-09-28 | 1986-06-10 | Institut Pasteur | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application |
US5443966A (en) * | 1989-06-20 | 1995-08-22 | Fairweather; Neil F. | Expression of tetanus toxin fragment C |
US5728383A (en) * | 1987-10-05 | 1998-03-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment of tumors of the central nervous system with immunotoxins |
US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
US5762926A (en) * | 1988-12-15 | 1998-06-09 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
US5780024A (en) * | 1995-06-23 | 1998-07-14 | The General Hospital Corp. | Superoxide dismutase/tetanus toxin fragment C hybrid protein |
US6005004A (en) * | 1994-08-05 | 1999-12-21 | Molecular / Structural Biotechnologies, Inc. | Lipophilic-polycationic delivery systems |
US6159948A (en) * | 1996-04-26 | 2000-12-12 | University Of Ottawa | Therapeutic and drug screening methods for the treatment and prevention of neuronal disease |
US20030004121A1 (en) * | 1997-08-14 | 2003-01-02 | Institut Pasteur | Hybrid proteins that migrate retrogradely and transynaptically into the CNS |
US20030083299A1 (en) * | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
US20040170651A1 (en) * | 1997-08-14 | 2004-09-02 | Sylvie Roux | In vivo modulation of neuronal transport |
US20050060761A1 (en) * | 1997-08-14 | 2005-03-17 | Rafael Vazquez-Martinez | Methods for direct visualization of active synapses |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US543578A (en) | 1895-07-30 | Island | ||
FR2470773B1 (en) | 1979-11-28 | 1983-01-28 | Pasteur Institut | |
CA1178949A (en) | 1979-11-28 | 1984-12-04 | Bernard Bizzini | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications |
GB8516442D0 (en) * | 1985-06-28 | 1985-07-31 | Wellcome Found | Cloned antigen |
US5004683A (en) | 1986-07-31 | 1991-04-02 | The Research Foundation Of State University Of New York | Means for detecting and analyzing neuroanatomy |
GB8829182D0 (en) * | 1988-12-14 | 1989-01-25 | Univ Birmingham | Surgical instrument |
US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US20050060764A1 (en) * | 2003-09-17 | 2005-03-17 | Susan Gregory | Mouse model for bone metabolism |
US5766948A (en) | 1993-01-06 | 1998-06-16 | The Regents Of The University Of California | Method for production of neuroblasts |
JPH09500540A (en) | 1993-07-30 | 1997-01-21 | メデヴァ ホールディングス ビー.ヴイ. | Vaccine composition |
US6551618B2 (en) * | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US5986054A (en) | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
US5738383A (en) * | 1996-11-20 | 1998-04-14 | Kobel, Inc. | Label assembly with patterned adhesive bands |
DK1234043T3 (en) | 1999-12-02 | 2004-07-19 | Health Prot Agency | Construction for delivery of therapeutic agents to neurocells |
WO2001052843A1 (en) | 2000-01-18 | 2001-07-26 | Mcgill University | β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS |
US20070092449A1 (en) | 2005-04-05 | 2007-04-26 | Rafael Vazquez-Martinez | Methods for direct visualization of active synapses |
-
2003
- 2003-09-16 US US10/662,808 patent/US7923216B2/en not_active Expired - Fee Related
-
2004
- 2004-09-15 EP EP04765752A patent/EP1663286B1/en not_active Not-in-force
- 2004-09-15 WO PCT/EP2004/010991 patent/WO2005025592A2/en active Application Filing
-
2006
- 2006-03-15 US US11/375,093 patent/US20060275327A1/en not_active Abandoned
-
2009
- 2009-11-23 US US12/623,776 patent/US20100260758A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4479940A (en) * | 1981-01-22 | 1984-10-30 | Institut Pasteur | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications |
US4594336A (en) * | 1982-09-28 | 1986-06-10 | Institut Pasteur | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application |
US5728383A (en) * | 1987-10-05 | 1998-03-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment of tumors of the central nervous system with immunotoxins |
US5762926A (en) * | 1988-12-15 | 1998-06-09 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
US5443966A (en) * | 1989-06-20 | 1995-08-22 | Fairweather; Neil F. | Expression of tetanus toxin fragment C |
US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
US6005004A (en) * | 1994-08-05 | 1999-12-21 | Molecular / Structural Biotechnologies, Inc. | Lipophilic-polycationic delivery systems |
US5780024A (en) * | 1995-06-23 | 1998-07-14 | The General Hospital Corp. | Superoxide dismutase/tetanus toxin fragment C hybrid protein |
US6159948A (en) * | 1996-04-26 | 2000-12-12 | University Of Ottawa | Therapeutic and drug screening methods for the treatment and prevention of neuronal disease |
US20030004121A1 (en) * | 1997-08-14 | 2003-01-02 | Institut Pasteur | Hybrid proteins that migrate retrogradely and transynaptically into the CNS |
US20040170651A1 (en) * | 1997-08-14 | 2004-09-02 | Sylvie Roux | In vivo modulation of neuronal transport |
US20050060761A1 (en) * | 1997-08-14 | 2005-03-17 | Rafael Vazquez-Martinez | Methods for direct visualization of active synapses |
US20030083299A1 (en) * | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110002914A1 (en) * | 1997-08-14 | 2011-01-06 | Institut Pasteur | Hybrid tetnus toxoid proteins that migrate retrogradely and transynaptically into the cns |
US20090324549A1 (en) * | 2007-01-29 | 2009-12-31 | Fondazione I.R.C.C.S. Istituto Neurologico "Carlo Besta" | Proteins and/or peptides for the prevention and/or treatment of neurodegenerative diseases |
WO2011066285A2 (en) * | 2009-11-24 | 2011-06-03 | Oregon Health & Science University | Peptide-based treatment for neurodegenerative diseases |
WO2011066285A3 (en) * | 2009-11-24 | 2011-11-03 | Oregon Health & Science University | Peptide-based treatment for neurodegenerative diseases |
Also Published As
Publication number | Publication date |
---|---|
US20040170651A1 (en) | 2004-09-02 |
EP1663286B1 (en) | 2012-09-05 |
US7923216B2 (en) | 2011-04-12 |
WO2005025592A2 (en) | 2005-03-24 |
US20100260758A1 (en) | 2010-10-14 |
WO2005025592A3 (en) | 2005-11-10 |
EP1663286A2 (en) | 2006-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060275327A1 (en) | In vivo modulation of neuronal transport | |
EP1735008A2 (en) | Tetanus toxin fusion protein for visualization of active synapses | |
US20090226468A1 (en) | Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the CNS | |
Salinas et al. | A hitchhiker's guide to the nervous system: the complex journey of viruses and toxins | |
Rummel | Two feet on the membrane: uptake of clostridial neurotoxins | |
CN104145015A (en) | Targeted lysosomal enzyme compounds | |
Verderio et al. | Internalization and proteolytic action of botulinum toxins in CNS neurons and astrocytes | |
Ferrari et al. | Synthetic self-assembling clostridial chimera for modulation of sensory functions | |
DE60008915T2 (en) | CONSTRUCTS FOR THE ADMINISTRATION OF THERAPEUTIC ACTIVE SUBSTANCES TO NEURON CELLS | |
Singh et al. | Clostridial neurotoxins as a drug delivery vehicle targeting nervous system | |
Connan et al. | Uptake of clostridial neurotoxins into cells and dissemination | |
Roux et al. | Internalization of a GFP-tetanus toxin C-terminal fragment fusion protein at mature mouse neuromuscular junctions | |
US20160051644A1 (en) | Botulinum Chimera Compositions for Axonal Regenerative Therapy During Spinal Cord Injury | |
US20070092449A1 (en) | Methods for direct visualization of active synapses | |
Wang et al. | Axonal transport of BDNF precursor in primary sensory neurons | |
US20100081197A1 (en) | In vivo modulation of neuronal transport | |
Höltje et al. | Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons | |
Leese et al. | Duplication of clostridial binding domains for enhanced macromolecular delivery into neurons | |
Bohnert et al. | Uptake and transport of clostridium neurotoxins | |
Fishman | 34—Tetanus toxin | |
EP4299125A1 (en) | Anti-mglur2 biparatopic nanobodies and uses thereof | |
Leese et al. | Toxicon: X | |
Foran | 9 Use of Neurotoxins as Drug Delivery Systems | |
Rodrigues | Crossing The Blood-brain Barrier Using Peptide Vectors For The Treatment Of Traumatic Brain Injury | |
WO2014059403A1 (en) | Chimeric proteins, compositions and methods for restoring cholinesterase function at neuromuscular synapses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INSTITUT PASTEUR, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROUX, SYLVIE;BRULET, PHILIPPE;CLOMENT, CECILE SAINT;AND OTHERS;REEL/FRAME:017945/0688;SIGNING DATES FROM 20060518 TO 20060523 Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROUX, SYLVIE;BRULET, PHILIPPE;CLOMENT, CECILE SAINT;AND OTHERS;REEL/FRAME:017945/0688;SIGNING DATES FROM 20060518 TO 20060523 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |